

1 **I. OVERVIEW OF THE FUNDING OPPORTUNITY**

2 **Broad Agency Announcement for Extramural Research (Program Specific) for the**  
3 **Department of Defense**

4 **Defense Health Program**

5 **Congressionally Directed Medical Research Programs**

6 **Joint Program Committee-1 (JPC-1)/Medical Simulation and Information Sciences (MSIS)**  
7 **Research Program**

8 **Psychological Health/Traumatic Brain Injury Research Program**  
9 **(PH/TBIRP)**

10 **Trauma Resiliency Immersive Adaptive Gaming Environment**  
11 **(TRIAGE) Award**

12 **Announcement Type: 1<sup>st</sup> Modification**

13 **Funding Opportunity Number: W81XWH-18-S-MSI1**

14 **Catalog of Federal Domestic Assistance Number: 12.420 Military Medical**  
15 **Research and Development**

16 **SUBMISSION AND REVIEW DATES AND TIMES**

- 17 • **Pre-Proposal/Pre-Application Submission Deadline:** 5:00 p.m. Eastern time (ET), June  
18 18, 2018
- 19 • **Invitation to Submit a Proposal/Application:** July 10, 2018
- 20 • **Proposal/Application Submission Deadline:** 11:59 p.m. ET, September 24, 2018
- 21 • **End of Proposal/Application Verification Period:** 5:00 p.m. ET, October 1, 2018
- 22 • **Peer Review:** November 2018
- 23 • **Programmatic Review:** January 2019

*This Broad Agency Announcement/Funding Opportunity Announcement (BAA) must be read in conjunction with the General Submission Instructions, which are available for downloading from Grants.gov. The General Submission Instructions are located under the “package tab” and can be downloaded by selecting the “Download Instructions” icon when previewing the submission package.*

**TABLE OF CONTENTS**

1

2 **I. OVERVIEW OF THE FUNDING OPPORTUNITY..... 1**

3 **II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY..... 3**

4 II.A. Program Description..... 3

5 II.A.1. Research Area of Interest ..... 4

6 II.A.2. Award Background..... 6

7 II.A.3. Anticipated Outcomes ..... 9

8 II.B. Award Information ..... 10

9 II.C. Eligibility Information..... 12

10 II.C.1. Eligible Applicants ..... 12

11 II.C.2. Cost Sharing..... 13

12 II.C.3. Other ..... 13

13 II.D. Proposal/Application and Submission Information ..... 14

14 II.D.1. Address to Request Proposal/Application Package..... 14

15 II.D.2. Content and Form of the Proposal/Application Submission ..... 14

16 II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) and System

17 for Award Management (SAM)..... 36

18 II.D.4. Submission Dates and Times..... 36

19 II.D.5. Intergovernmental Review ..... 37

20 II.D.6. Funding Restrictions..... 37

21 II.D.7. Other Submission Requirements ..... 39

22 II.E. Proposal/Application Review Information ..... 39

23 II.E.1. Criteria ..... 39

24 II.E.2. Proposal/Application Review and Selection Process ..... 41

25 II.E.3. Integrity and Performance Information..... 42

26 II.E.4. Anticipated Announcement and Federal Award Dates..... 42

27 II.F. Federal Award Administrative Information..... 42

28 II.F.1. Federal Award Notices..... 42

29 II.F.2. Administrative and National Policy Requirements..... 43

30 II.F.3. Reporting..... 44

31 II.G. Federal Awarding Agency Contacts..... 45

32 II.G.1. CDMRP Help Desk ..... 45

33 II.G.2. Grants.gov Contact Center ..... 45

34 II.H. Other Information..... 46

35 II.H.1. Administrative Actions..... 46

36 II.I. Proposal/Application Submission Checklist..... 49

37 **APPENDIX I: ACRONYMS AND ABBREVIATIONS ..... 51**

38

## 1 **II. DETAILED INFORMATION ABOUT THE FUNDING** 2 **OPPORTUNITY**

3 ***New for 2018: Proposal/Application submission by extramural organizations through***  
4 ***Grants.gov requires use of the Workspace interface, which separates the proposal/***  
5 ***application package into individual forms. Applicants must create a Workspace in***  
6 ***Grants.gov, complete the required forms, and submit their proposal/application***  
7 ***Workspace package.***

8 This Funding Opportunity Announcement is a Broad Agency Announcement (BAA) for the  
9 Fiscal Year 2018 (FY18) Psychological Health/Traumatic Brain Injury Research Program  
10 (PH/TBIRP) Trauma Resiliency Immersive Adaptive Gaming Environment (TRIAGE) Award.  
11 For the remainder of the announcement, this BAA will be referenced as TRIAGE. Specific  
12 submission information and additional administrative requirements can be found in the document  
13 titled “General Submission Instructions,” available in Grants.gov along with this BAA.

14 This BAA (Program Specific) is intended to solicit extramural research and development ideas  
15 and is issued under the provisions of the Competition in Contracting Act (CICA) of 1984 (Public  
16 Law 98-369), as implemented in Federal Acquisition Regulation (FAR) 6.102(d)(2) and 35.016  
17 and in Department of Defense (DoD) Grant and Agreement Regulations (DoDGARs) 22.315. In  
18 accordance with FAR 35.016, projects funded under this BAA must be for basic and applied  
19 research and that part of development not related to the development of a specific system or  
20 hardware procurement. Projects must be for scientific study and experimentation directed  
21 toward advancing the state-of-the-art or increasing knowledge or understanding rather than  
22 focusing on a specific system or hardware solution. Research and development funded through  
23 this BAA is intended and expected to benefit and inform both military and civilian medical  
24 practice and knowledge.

25 **This BAA is intended for extramural applicants only. For definitions and additional**  
26 **information, see [Section II.C.1](#).** (There is a separate BAA for intramural applicants applying  
27 through intramural organizations that is available through the eBRAP [<https://eBRAP.org/>] under  
28 the funding opportunity number W81XWH-18-DMRDP-MSIS-TRI).

- 29 • In accordance with FAR 35.017, Federally Funded Research and Development Centers  
30 (FFRDCs) are not eligible to directly receive awards under this BAA. However, teaming  
31 arrangements between FFRDCs and eligible organizations are allowed if permitted under the  
32 sponsoring agreement between the Federal Government and the specific FFRDC.

### 33 **II.A. PROGRAM DESCRIPTION**

34 Proposals/Applications to the FY18 PH/TBIRP are being solicited for the Defense Health  
35 Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research  
36 Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of  
37 Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP)  
38 Research, Development, Test, and Evaluation (RDT&E) appropriation. The U.S. Army Medical  
39 Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research  
40 Programs (CDMRP) provides PH/TBIRP management support aligned with specific DHA

DoD FY18 PH/TBIRP Trauma Resiliency Immersive Adaptive Gaming Environment  
(TRIAGE) Award

1 research program areas, including the Joint Program Committee 1 (JPC-1)/Medical Simulation  
2 and Information Sciences (MSIS) Research Program. This BAA and subsequent awards will be  
3 managed and executed by CDMRP with strategic oversight from the JPC-1/MSIS.

4 The PH/TBIRP was established by Congress in FY07 in response to the devastating impact of  
5 traumatic brain injury (TBI) and psychological health (PH) issues, including post-traumatic  
6 stress disorder (PTSD), on our deployed Service members in Iraq and Afghanistan. The  
7 PH/TBIRP mission is to establish, fund, and integrate both individual and multiagency research  
8 efforts that will lead to improved prevention, detection, and treatment of PH issues and TBI. The  
9 vision of the PH/TBIRP is to prevent, mitigate, and treat the effects of traumatic stress and TBI  
10 on function, wellness, and overall quality of life for Service members as well as their caregivers  
11 and families.

12 The mission of the JPC-1/MSIS is to explore the implications of models and technology for  
13 medical education and training for the provision, management, and support of health services in  
14 the military. The JPC-1/MSIS plans, coordinates, and oversees a responsive world-class, tri-  
15 Service science and technology program focused on three portfolios of research: (1) Medical  
16 Simulation (Med Sim), focused on improving military medical training through medical  
17 modeling, simulation, and educational training tools; (2) Health Information Technology (HIT),  
18 focused on improving the use and sharing of health-related data for better strategic planning,  
19 process development, and software applications; and (3) Multi-Domain Battle, an operational  
20 environment involving greater dispersion and near isolation over great distances, which is likely  
21 to cause severe restrictions on mobility for medical missions and shortfalls in both human and  
22 materiel human resources due to area denial challenges. Combat units will need to be more self-  
23 sufficient and less dependent on logistical support. Combatant commanders with increased sick  
24 or wounded Service members will face degradation of medical resources and encumbered  
25 combat effectiveness without new combat casualty management and Force multiplication  
26 strategies.

27 The JPC-1/MSIS Medical Simulation and Training Technologies Steering Committee provides  
28 programmatic funding recommendations for DHP RDT&E medical research dollars related to  
29 medical training and education efforts to advance the development and integration of simulation-  
30 based training systems. The Steering Committee provided the strategy for which this BAA's  
31 topic was conceived.

### 32 **II.A.1. Research Area of Interest**

33 The FY18 JPC-1/MSIS PH/TBIRP TRIAGE Award is seeking proposals/applications  
34 developing and evaluating an innovative protocol for virtual immersive gaming interoperable  
35 components that will increase medical care provider performance, adaptability, and agility in  
36 stress-inducing contexts related to Roles of Care 1-3. These resulting TRIAGE proof-of-concept  
37 models should be developed for relevancy to medical simulation training across the continuum  
38 of care and address the needs and priorities of the military medical training community, with  
39 applicability to civilian groups as well.

40 TRIAGE is a line of research that maps to DHA's Warfighter Preparation, Resilience,  
41 Enhancement and Protection (WarPREP) program, under the JPC-1/MSIS Med Sim portfolio. It

1 addresses the capability gap to provide resiliency training prior to deployment to better elicit  
2 higher performance under pressure. The ultimate goal of this research is to increase medical care  
3 providers' readiness and resiliency through increases in performance, adaptability, and agility in  
4 the diverse high pressure and stressful context anticipated in Roles of Care 1-3 as defined below:

- 5 • Role 1 – Point of injury care. First responder capabilities including immediate lifesaving  
6 measures at the point of injury in deployed/operational environments.
- 7 • Role 2 – Forward resuscitative care including advanced trauma/emergency medical  
8 treatment. Some Role 2 sites are expanded to include additional medical services and  
9 ancillary support services (e.g., laboratory, pharmacy, radiology) to provide more robust care  
10 for larger Patient at Risk (PAR) populations. Role 2 also includes en route care, defined as  
11 care required to maintain the phase treatment initiated prior to evacuation and the  
12 sustainment of the patient's medical condition during evacuation.
- 13 • Role 3 – Theater hospitalization including robust care for resuscitation, surgery, and post-  
14 operative care.

15 **TRIAGE is not aimed at resiliency training *prior* to stress exposure in order to mitigate**  
16 **stress-induced performance loss;** instead, it seeks a gaming interoperable component that  
17 elicits cognitively demanding problem-solving and decision-making under high-stress scenarios  
18 in order to increase performance, adaptability, and agility that also translates to real-world  
19 scenarios. By using virtual, gaming simulations, medical care providers can undergo exercises  
20 under high-stress scenarios in diverse, relevant settings before their skills are needed in the field.  
21 The current announcement focuses on high-stress, immersive three-dimensional (3D) gaming  
22 interoperable components that increase participant performance, adaptability, and agility through  
23 repeated rehearsals of a medical scenario in which the participants can learn to adapt their  
24 behavior to:

- 25 • Alter the course of the scenario;
- 26 • Influence scenario outcomes; and
- 27 • Reduce or control the level of stress presented to the participant.

28 **For the purposes of this BAA, the research is *not* for the development of a new gaming**  
29 **platform;** instead, it should leverage existing, validated platforms to develop a new interoperable  
30 component. Reliance on open source and accessible platforms is preferred. Anticipated  
31 technology readiness level (TRL) desired by the end of the base year of research is TRL 4, which  
32 constitutes evidence that the proof-of-concept model can be implemented into a data/knowledge  
33 system whose components are integrated and work together, and the proof-of-concept model has  
34 been evaluated within a laboratory-type environment. A preliminary interface will be created,  
35 and information the accessibility of this proof-of-concept and if there are open source or publicly  
36 accessible components should also be stated.

37 This award is not limited to research in a specific medical domain; all areas of medicine are  
38 encouraged to submit (dental, dermatology, obstetrics, ophthalmology, surgical fields, etc.).

1 However, medical domains that have higher alignment with treatment of traumatic and acute  
2 injuries/multi-casualties will be more favorably viewed.

3 The outcomes of the research will allow data/information/knowledge into the proof-of-concept  
4 model. The model needs to be tested in a laboratory-type environment, *preferably by a*  
5 *subawardee with no active participation in the development of the model.* Actual interfaces  
6 will need to be described and defined in the outcome, but functionality of the entire defined  
7 interface does not need to be demonstrated in the delivered proof-of-concept.

8 Proposal/Application submissions to the FY18 PH/TBIRP TRIAGE Award should not only  
9 include the design and the methodologies to create the TRIAGE proof-of-concept interoperable  
10 component, but also include a protocol for a resiliency model that is embedded within a stressful  
11 medical scenario and evaluation of the resiliency effectiveness in relevant contexts in a pilot  
12 group of participants, using wearable or non-wearable sensors or other assays to measure stress,  
13 performance, and other relevant metrics.

14 The proposal/application objectives should be focused on the development of an interoperable  
15 component that aims to include all of the following attributes, in order of importance:

- 16 • Stress-inducing immersive scenarios where the stress-level can be unpredictable, varied or  
17 dosed;
- 18 • Repeated exposure to scenarios where participant behavior and decisions influence the  
19 course of the scenario to tailor the scenario to the participant; and
- 20 • Increases in performance that can be objectively measured.

21 It is encouraged that applicants include the following features in the model:

- 22 • Adaptive coaching component that can give feedback based on the phase of learning or  
23 turned off to allow participants to play through; and
- 24 • Simulations on medical safety issues seen in the field (e.g., triaging).

25 The proposed research outcomes are intended to have broad applicability not only with the  
26 content, but also with underlying architecture or models to allow more open communication now  
27 as well as in future efforts. Although discouraged, the proposed research *may* include  
28 proprietary tools. The results from this research are expected to be submitted to a peer-reviewed  
29 journal for dissemination and be made available for Government use.

## 30 **II.A.2. Award Background**

31 For additional background information please see the [references listed below](#).

32 Emergency and traumatic scenarios require medical care providers to maintain performance in  
33 the face of intense stress. This ability to maintain performance during and after high pressure or  
34 traumatic scenarios composes the concept of resiliency and is essential to the maintenance of a  
35 fit and ready Force. Resiliency related to maintaining cognitive performance during stress

1 includes the ability to maintain adaptability, agility, decision-making and problem-solving skills,  
2 mental flexibility, attention, and memory. As many of these cognitive skills are integral to the  
3 delivery of effective care in complex medical scenarios, such as in mass casualty events, it is  
4 important to gradually build these skills under stress exposure while undergoing medical  
5 training. Preparation programs using medical simulation can incorporate stress exposure to  
6 scenarios in order to practice strategies to maintain cognitive performance in order to build and  
7 strengthen resiliency skills. Ideally, the gains in performance under stress obtained in training  
8 are long-lasting and generalize to diverse settings and challenges anticipated in real-world  
9 scenarios and the operational space.

10 The ability to prepare for increased agility and adaptability will likely become increasingly  
11 important in anticipated future deployments to variable and diverse operational settings.  
12 Considerable attention is being paid to developing new and modifying existing training aimed at  
13 promoting personal readiness and resilience in “training on demand” formats that are more  
14 amenable to the operational landscape. The DoD has put an emphasis on developing resilience  
15 in its Force, as specified in the DoD Instruction 6490.09 subject: DoD Directors of Psychological  
16 Health. The emphasis on the performance building aspects of resiliency are reiterated in the  
17 Headquarters, Department of the Army, Executive Order (HQDA EXORD) 086-16 (Human  
18 Dimension 22 DEC 15), which states that “The Army has the capability and capacity to optimize  
19 the human performance of every Soldier and civilian...” Objective 1.3 of this health and fitness  
20 goal states a priority to “Enhance soldier and army civilian health and physical readiness through  
21 an individualized training system that improves human performance and resilience...” and to  
22 “train teams of army professionals to improve and thrive in ambiguity and chaos.” Efforts to  
23 prepare for increased decision-making, problem-solving, adaptability, and agility are integral to  
24 success in these ever-changing, ambiguous, chaotic, and diverse operational environments. The  
25 ability to maintain medical skills in high-stress scenarios extends beyond the military as civilian  
26 organizations are faced with mass casualty events from natural disasters, mass shootings, and  
27 other mass casualty events facing the public.

28 Ongoing efforts in this concept of Stress Management Training (SMT) have shown growing  
29 evidence for efficacy in reducing the negative outcomes of stress on performance and health (see  
30 Pallavicini et al., 2016, and Leppin et al., 2014, for review). While resiliency exposure in the  
31 absence of stress has demonstrated efficacy in decreased performance losses for future stress  
32 exposure, this announcement is focused on Stress Exposure Training (SET) or Stress Inoculation  
33 Training (SIT) paradigms that use training under stress. Similar paradigms in SET or SIT have  
34 been used by multiple programs to train military members on both combat and medical skills,  
35 such as in Squad Overmatch; virtual reality adaptive simulation (VRAS); and Stress Resilience  
36 in Virtual Environments (STRIVE) (Rizzo et al., 2012). The outcomes of these programs can be  
37 influenced by the content of the exercise, as well as the structure of the setting, timing of stress,  
38 format of delivery, sequence of events, number, or repetition of stress exposure, and the type or  
39 perceived controllability of the stressor. Ideally, these programs would cause long-lasting gains  
40 in performance, adaptability, and agility in participants as compared to subjects not exposed to  
41 stress, and these gains would translate to contexts beyond the scenarios.

42 Animal studies on resilience have demonstrated that repeated exposure to stress in certain  
43 formats, namely in controllable or escapable stress scenarios, can lead to long-lasting resilience  
44 that generalizes beyond the initial stress context to novel adverse events (Seligman and Maier,

1 1967; Maier and Watkins, 2005). Conversely, animals exposed to the same stressor, but without  
2 the ability to control or turn off the stressor, eventually demonstrated learned helplessness and  
3 behaviors related to anxiety- and depression-like behaviors in subsequent assays. The animals  
4 with the option to learn how to control or escape a stressor over repeated iterations not only  
5 showed protection for the negative effects of stress exposure, but also in some cases, improved  
6 performance as compared to a non-stressed comparison group (Maier and Watkins, 2010). Some  
7 initial work has demonstrated similar behavioral effects of controllable stress in humans;  
8 however, more work is needed (Hartley et al., 2015).

9 Simulation of stressful scenarios provides an ideal opportunity to provide repeated, safe exposure  
10 to controllable or uncontrollable stressors. Virtual simulation provides a unique opportunity to  
11 control stress exposure to participants in combat care scenarios and allows for relevant scenarios  
12 to be explored. Virtual simulation allows for a diversity of scenarios; preliminary evidence  
13 shows it can reduce participants' responses to stress (for review, see Pallavicini et al., 2016).  
14 Initial attempts to implement SET with virtual or gaming simulations have been conducted;  
15 however, more data are needed on the aspects of stress controllability and ability to generalize  
16 performance gains to novel scenarios. Additionally, simulation provides an opportunity for  
17 participants to learn over multiple iterations how to control the scenario, and therefore stress  
18 exposure, through their actions and performance in the simulation. Allowing the participant to  
19 actively alter the stress of the scenario through his or her own actions provides an opportunity to  
20 replicate the controllable stress paradigms. Virtual simulation provides a unique opportunity to  
21 control stress exposure to participants in combat care scenarios and allows for a diversity of  
22 scenarios; preliminary evidence shows it can reduce participants' responses to stress (for review,  
23 see Pallavicini et al., 2016).

24 The anticipated long-term vision includes, but is not limited to: (1) incorporation of an existing,  
25 live, virtual gaming platform; (2) scalable, modular, interoperable, flexible preparation proof-of-  
26 concept component that can be adapted for diverse military or civilian needs; (3) interoperability  
27 with existing virtual gaming platforms; (4) sustainable maintenance and updates of the  
28 interoperable component; (5) opportunities for commercialization; and (6) possibility of  
29 changing or modifying existing policies and/or military medical preparation curricula and/or  
30 objectives.

#### 31 References:

- 32 1. Pallavicini, F., Argenton, L., Toniuzzi, N., Aceti, L., and Mantovani, F. 2016. Virtual reality  
33 applications for stress management training in the Military. *Aerospace Medicine and Human*  
34 *Performance*, 87(12): 1021-1030. PMID: 28323588.
- 35 2. Leppin, A.L., Bora, P.R., Tilburt, J.C., Gionfriddo, M.R., Zeballos-Palacios, C., Dulohery,  
36 M.M., Sood, A., Erwin, P.J., Brito, J.P., Boehmer, K.R., and Montori, V.M. 2014. The  
37 efficacy of resiliency training programs: a systemic review and meta-analysis of randomized  
38 trials. *PLoS One*, 9(10): e111420. PMID: 25347713.
- 39 3. Rizzo, A., Buckwalter, J.G., John, B., Newman, B., Parsons, T., Kenny, P., and Williams, J.  
40 2012. STRIVE: Stress resilience in virtual environments: a pre-deployment VR system for

1 training emotional coping skills and assessing chronic and acute stress responses. *Studies in*  
2 *Health Technology and Informatics*, 173: 379-385. PMID: 22357022.

3 4. Seligman, M.E. and Maier, S.F. 1967. Failure to escape traumatic shock. *Journal of*  
4 *Experimental Psychology*, 74(1):1-9. PMID: 6032570.

5 5. Maier, S.F. and Watkins, L.R. 2005. Stressor controllability and learned helplessness: the  
6 roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. *Neuroscience*  
7 *and Biobehavioral Reviews*, 29(4-5): 829-841. PMID: 15893820.

8 6. Maier, S.F. and Watkins, L.R. 2010. Role of the medial prefrontal cortex in coping and  
9 resilience. *Brain Research*, 1355: 52-60. PMID: 20727864.

10 7. Hartley, C.A., Gorun, A., Reddan, M.C., Ramirez, F., and Phelps, E.A. 2014. Stressor  
11 controllability modulates fear extinction in humans. *Neurobiology of Learning and Memory*,  
12 113: 149-156. PMID: 24333646.

### 13 **II.A.3. Anticipated Outcomes**

14 The anticipated outcomes of research supported by the FY18 PH/TBIRP TRIAGE Award are  
15 described below (in no particular order).

- 16 • A proof-of-concept simulation.
- 17 • Empirical definitions to the outcome measures and metrics that will be objectively or  
18 subjectively collected and provide the measurement tools used.
- 19 • A description of the scenarios or explanation of how scenarios can be easily customized or  
20 adapted.
- 21 • Plans to evaluate gains in outcome measures.
- 22 • Evaluation of effects on outcome measures (performance, ability, adaptability, stress levels)  
23 whether positive, negative, or neutral, which will be analyzed and recorded in the technical  
24 reports and, eventually, in the final report.
- 25 • Instructions on the use of the tool as well as definitions, descriptions of measuring devices  
26 used, range of acceptable metrics/evaluation criteria, and a draft user manual that will be  
27 provided to the Government.
- 28 • Plans for sustainable maintenance and updates of the interoperable component including  
29 possible commercialization pathways.
- 30 • An interoperable component that can be or is designed to be scalable to incorporate scenarios  
31 with multiple players (team setting).
- 32 • An interoperable component that can be used across the Military Services. Research  
33 outcomes, analysis, methodologies, and conclusions will be disseminated and propagated not

1 only to the military and the Government but also to the public at large through publication in  
2 peer-reviewed journals. It is anticipated that scenarios could be relevant across the military,  
3 Department of Veteran Affairs (VA), academic, inpatient, outpatient clinics, rural healthcare  
4 settings, private and public hospitals, and international healthcare situations.

## 5 **II.B. AWARD INFORMATION**

6 The anticipated total costs budgeted for the entire period of performance for an FY18 TRIAGE  
7 Award will not exceed \$1.3 million (M). Refer to [Section II.D.6](#), Funding Restrictions, for  
8 detailed funding information.

9 The USAMRAA will negotiate the award types for proposals/applications selected for funding.  
10 The Federal Grant and Cooperative Agreement Act of 1977, United States Code, Title 31,  
11 Sections 6301-6308 (31 USC 6301-6308), provides the legal criteria to select a procurement  
12 contract or an assistance agreement.

13 **Extramural Organizations:** An assistance agreement (grant or cooperative agreement) is  
14 appropriate when the Federal Government transfers a “thing of value” to a “state, local  
15 government,” or “other recipient” to carry out a public purpose of support or stimulation  
16 authorized by a law of the United States, instead of acquiring property or service for the direct  
17 benefit and use of the U.S. Government. An assistance agreement can take the form of a grant or  
18 cooperative agreement. If “no substantial involvement” on the part of the funding agency is  
19 anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement  
20 on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC  
21 6305) and the award will identify the specific substantial involvement. Substantial involvement  
22 may include collaboration, participation, or intervention in the research to be performed under  
23 the award. A contract is required when the principal purpose of the instrument is to acquire  
24 property or services for the direct benefit or use of the U.S. Government. The award type, along  
25 with the start date, will be determined during the negotiation process.

26 Please see Appendix 2 of the General Submission Instructions for more information.

### 27 **Research involving Human Anatomical Substances, Human Subjects, or Human Cadavers:**

28 All DoD-funded research involving new and ongoing research with human anatomical  
29 substances, human subjects, or human cadavers must be reviewed and approved by the  
30 USAMRMC Office of Research Protections (ORP), Human Research Protection Office (HRPO),  
31 prior to research implementation. This administrative review requirement is in addition to the  
32 local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC  
33 approval at the time of submission is not required. The HRPO is mandated to comply with  
34 specific laws and requirements governing all research involving human anatomical substances,  
35 human subjects, or human cadavers that is supported by the DoD. These laws and requirements  
36 will necessitate information in addition to that supplied to the IRB/EC. *Allow a minimum of 2*  
37 *to 3 months for HRPO regulatory review and approval processes.* Additional time for  
38 regulatory reviews may be needed for clinical studies taking place in international settings.  
39 When possible, protocols should be written for research with human subjects and/or human  
40 anatomical substances that are specific to the DoD-supported effort outlined in the submitted  
41 proposal/application as a stand-alone study. Submission to HRPO of protocols involving more

1 than the scope of work in the DoD-funded award will require HRPO review of the entire  
2 protocol (DoD and non-DoD funded). DoD human subjects protection requirements may be  
3 applied to non-DoD funded work and necessitate extensive revisions to the protocol. Refer to  
4 the General Submission Instructions, Appendix 1, and the Human Subject Resource Document  
5 available on the eBRAP “Funding Opportunities & Forms” web page  
6 (<https://ebrap.org/eBRAP/public/Program.htm>) for additional information.

7 **Use of DoD or Department of Veterans Affairs (VA) Resources:** If the proposed research  
8 involves access to active duty military patient populations and/or DoD resources or databases,  
9 the applicant is responsible for demonstrating such access at the time of proposal/application  
10 submission and should develop a plan for maintaining access as needed throughout the proposed  
11 research. Access to target active duty military patient population(s) and/or DoD resource(s) or  
12 database(s) should be confirmed by including a letter of support, signed by the lowest-ranking  
13 person with approval authority.

14 If the proposed research involves access to VA patient populations, VA study resources and  
15 databases, and/or VA research space and equipment, VA applicants must have a plan for  
16 obtaining and maintaining access throughout the proposed research. Access to VA patients,  
17 resources, and/or VA research space should be confirmed by including a letter of support from  
18 the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the  
19 Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief.  
20 If appropriate, the proposal/application should identify the VA-affiliated non-profit corporation  
21 (NPC) as the applicant institution for VA applicants. If the VA NPC is not identified as the  
22 applicant institution for administering the funds, the proposal/application should include a letter  
23 from the VA ACOS/R&D confirming this arrangement and identifying the institution that will  
24 administer the funds associated with the proposed research.

25 Access to certain DoD or VA patient populations, resources, or databases may only be obtained  
26 by collaboration with a DoD or VA investigator who has a substantial role in the research and  
27 may not be available to a non-DoD or non-VA investigator if the resource is restricted to DoD or  
28 VA personnel. Applicants should be aware of which resources are available to them if the  
29 proposed research involves a non-DoD or non-VA investigator collaborating with the DoD  
30 and/or VA. If access cannot be confirmed at the time of proposal/application submission, the  
31 Government reserves the right to withdraw or revoke funding until the PI has demonstrated  
32 support for and access to the relevant population(s) and/or resource(s). Refer to [Section](#)  
33 [II.D.2.b.ii, Full Proposal/Application Submission Components](#), for detailed information.

34 ***The CDMRP intends that information, data, and research resources generated under awards***  
35 ***funded by this BAA be made available to the research community (which includes both***  
36 ***scientific and consumer advocacy communities) and to the public at large. For additional***  
37 ***guidance, refer to the General Submission Instructions, Appendix 2, Section K.***

1 **II.C. ELIGIBILITY INFORMATION**

2 **II.C.1. Eligible Applicants**

- 3 • An *extramural applicant* is defined as all those not included in the definition of intramural  
4 applicants below.
- 5 • An *intramural applicant* is defined as a DoD military or civilian employee working within a  
6 DoD laboratory, DoD military treatment facility, or working in a DoD activity embedded  
7 within a civilian medical center. This BAA is intended for extramural applicants only.  
8 (There is a separate BAA for intramural applicants applying through intramural organizations  
9 that is available through the eBRAP [<https://eBRAP.org/>] under the funding opportunity  
10 number W81XWH-18-DMRDP-MSIS-TRI). Applicants submitting through their intramural  
11 organizations are reminded to coordinate receipt and commitment of funds through their  
12 respective resource managers.
- 13 • Submissions from intramural applicants to this BAA will be rejected. *It is permissible,*  
14 *however, for an intramural investigator to be named as a collaborator on a*  
15 *proposal/application submitted through an extramural organization. In this case, the*  
16 *proposal/application must include a letter from the collaborator’s Commander or*  
17 *Commanding Officer at the intramural organization that authorizes the collaborator’s*  
18 *involvement.* For more information, refer to the General Submission Instructions, Section  
19 II.C.

20 **II.C.1.a. Organization: All extramural organizations, including international**  
21 **organizations, are eligible to apply.**

22 Awards are made to organizations only. Organizations eligible to apply include national,  
23 international, for-profit, non-profit, public, and private organizations. Refer to the General  
24 Submission Instructions, Appendix 3, for general eligibility information.

25 **NOTE:** In accordance with FAR 35.017, FFRDCs are not eligible to directly receive awards  
26 under this BAA. However, teaming arrangements between FFRDCs and eligible organizations  
27 are allowed so long as they are permitted under the sponsoring agreement between the Federal  
28 Government and the specific FFRDC.

29 The USAMRMC is committed to supporting small businesses. Small business, Veteran-owned  
30 small business, Service-disabled Veteran-owned small business, HUBZone small business, small  
31 disadvantaged business, and woman-owned small business concerns must be given the  
32 maximum practical opportunity to participate through subawards on research proposals/  
33 applications submitted through the BAA.

34 **Government Agencies Within the United States:** Local, state, and Federal Government  
35 agencies are eligible to the extent that proposals/applications do not overlap with their fully  
36 funded internal programs. Such agencies are required to explain how their proposals/  
37 applications do not overlap with their internal programs.

1 Proposals/Applications for this BAA may only be submitted by extramural organizations.  
2 Applicants from an intramural organization should apply through eBRAP under the funding  
3 opportunity number W81XWH-18-DMRDP-MSIS-TRI. These terms are defined below.

4 **Extramural Organization:** An eligible non-DoD organization. Examples of extramural  
5 organizations include academia, biotechnology companies, foundations, Government, and  
6 research institutes.

7 **Intramural DoD Organization:** A DoD laboratory, DoD military treatment facility, and/or  
8 DoD activity embedded within a civilian medical center. *If an investigator at an intramural  
9 organization is named as a collaborator on a proposal/application submitted through an  
10 extramural organization, the proposal/application must include a letter from the  
11 collaborator's Commander or Commanding Officer at the intramural organization that  
12 authorizes the collaborator's involvement.*

13 **Note:** Proposals/Applications from an intramural DoD organization or from an extramural non-  
14 DoD Federal organization may be submitted through a research foundation.

15 The USAMRAA makes awards to eligible organizations, not to individuals.

#### 16 **II.C.1.b. Principal Investigator**

17 Independent investigators at all academic levels of professorship appointments (or industrial  
18 equivalent) are eligible to submit proposals/applications. Training fellows, at the graduate or  
19 postdoctoral level, are not eligible to apply for this solicitation.

20 An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or  
21 affiliated with, an eligible organization.

22 The CDMRP encourages all applicants to participate in a digital identifier initiative through  
23 Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier  
24 can be done online at <http://orcid.org/>.

#### 25 **II.C.2. Cost Sharing**

26 Cost sharing/matching is not an eligibility requirement.

#### 27 **II.C.3. Other**

28 Organizations must be able to access **.gov** and **.mil** websites in order to fulfill the financial and  
29 technical deliverable requirements of the award and submit invoices for payment.

30 Each investigator may submit only one FY18 PH/TBIRP TRIAGE Award proposal/application  
31 as a PI.

32 **Subcontracting Plan:** If the resultant award is a contract that exceeds \$700,000 and the offeror  
33 is other than a small business, the contractor will be required to submit a subcontracting plan for  
34 small business and small disadvantaged business concerns, in accordance with FAR 19.704 and

1 Defense Federal Acquisition Regulation Supplement, Subpart 219.704 (DFARS 219.704). A  
2 mutually agreeable plan will be incorporated as part of the resultant contract.

3 For general information on required qualifications for award recipients, refer to the General  
4 Submission Instructions, Appendix 3.

5 In addition to other information provided herein, by submitting a proposal/application and  
6 accepting an award, the organization is: (1) certifying that the applicants' credentials have been  
7 examined and (2) verifying that the applicants are qualified to conduct the proposed study and to  
8 use humans as research subjects, if proposed. Applicants include all individuals, regardless of  
9 ethnicity, nationality, or citizenship status, who are employed by, or affiliated with, an eligible  
10 organization.

11 Refer to [Section II.H.1, Administrative Actions](#), for a list of administrative actions that may be  
12 taken if a pre-proposal/pre-application or proposal/application does not meet the administrative,  
13 eligibility, or ethical requirements defined in this BAA.

## 14 **II.D. PROPOSAL/APPLICATION AND SUBMISSION INFORMATION**

### 15 **II.D.1. Address to Request Proposal/Application Package**

16 eBRAP is a multifunctional web-based system that allows applicants to submit their  
17 pre-proposals/pre-applications electronically through a secure connection, to view and edit the  
18 content of their pre-proposals/pre-applications and full proposals/applications, to receive  
19 communications from the CDMRP, and to submit documentation during award negotiations and  
20 period of performance.

21 **Extramural Submissions:** Pre-proposal/Pre-application content and forms must be accessed and  
22 submitted at [eBRAP.org](https://eBRAP.org). Full proposal/application packages must be accessed and submitted at  
23 Grants.gov.

24 **Intramural DoD Submissions:** Pre-proposal/Pre-application content and forms and full  
25 proposal/application packages for funding opportunity number W81XWH-18-DMRDP-MSIS-  
26 TRI must be accessed and submitted at [eBRAP.org](https://eBRAP.org).

27 Contact information for the CDMRP Help Desk and the Grants.gov Contact Center can be found  
28 in [Section II.G, Federal Awarding Agency Contacts](#).

### 29 **II.D.2. Content and Form of the Proposal/Application Submission**

30 Submission is a two-step process requiring both *pre-proposal/pre-application* and *full*  
31 *proposal/application* as indicated below. The submission process should be started early to  
32 avoid missing deadlines. There are no grace periods.

33 **Pre-Proposals/Pre-Application Submissions:** All pre-proposals/pre-applications for both  
34 extramural and intramural organizations must be submitted through eBRAP  
35 (<https://eBRAP.org>).

1 **Full Proposal/Application Submissions:** Full proposals/applications must be submitted  
2 through the online portals as described below.

3 ***Submitting Extramural Organizations:*** Full proposals/applications from extramural  
4 organizations must be submitted through a Grants.gov Workspace. Proposals/Applications  
5 submitted by extramural organizations (e.g., research foundations) on behalf of intramural DoD  
6 or other Federal organizations or investigators will be considered extramural submissions.  
7 Proposals/Applications from extramural organizations, including non-DoD Federal  
8 organizations, received through eBRAP will be withdrawn. See definitions in [Section II.C.1,](#)  
9 [Eligible Applicants.](#)

10 ***Submitting Intramural DoD Organizations:*** Intramural DoD organizations may submit full  
11 proposals/applications for funding opportunity number W81XWH-18-DMRDP-MSIS-TRI to  
12 either eBRAP or Grants.gov. Intramural DoD organizations that are unable to submit to  
13 Grants.gov should submit through eBRAP. Intramural DoD organizations with the capability to  
14 submit through Grants.gov may submit following the instructions for extramural submissions  
15 through Grants.gov or may submit to eBRAP.

16 ***For Both Extramural and Intramural Applicants:*** A key feature of eBRAP is the ability of an  
17 organization’s representatives and PIs to view and modify the full proposal/application  
18 submissions associated with them. eBRAP will validate full proposal/application files against  
19 the specific BAA requirements, and discrepancies will be noted in an email to the PI and in the  
20 “Full Application Files” tab in eBRAP. It is the applicant’s responsibility to review all  
21 proposal/application components for accuracy as well as ensure proper ordering as specified in  
22 this BAA.

23 ***The proposal/application title, eBRAP log number, and all information for the PI, Business***  
24 ***Official(s), performing organization, and contracting organization must be consistent***  
25 ***throughout the entire pre-proposal/pre-application and full proposal/application submission***  
26 ***process.*** Inconsistencies may delay proposal/application processing and limit or negate the  
27 ability to view, modify, and verify the proposal/application in eBRAP. If any changes need to be  
28 made, the applicant should contact the CDMRP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or  
29 301-682-5507 prior to the proposal/application submission deadline.

### 30 **II.D.2.a. Step 1: Pre-Proposal/Pre-Application Submission Content**

31 Pre-proposals/Pre-applications should describe specific ideas or projects that pertain to any of the  
32 areas described under “Program Description” in this BAA. A pre-proposal/pre-application must  
33 include a brief description of the scientific methods and design to address the problem as  
34 described below. Brochures or other descriptions of general organizational or individual  
35 capabilities will not be accepted as a pre-proposal/pre-application. ***DO NOT include any***  
36 ***proprietary information in the pre-proposal/pre-application.***

37 During the pre-proposal/pre-application process, each submission is assigned a unique log  
38 number by eBRAP. This unique eBRAP log number will be needed during the full  
39 proposal/application submission process.

1 To begin the pre-proposal/pre-application process, first select whether the submitting  
2 organization is extramural or intramural, then confirm your selection or cancel (*the selection*  
3 *chosen should be “extramural” as only extramural applicants are eligible to apply to this BAA*).  
4 **Incorrect selection of extramural or intramural submission type will delay processing.**

5 If an error has been made in the selection of extramural versus intramural and the pre-proposal/  
6 pre-application submission deadline has passed, the PI or Business Official must contact the  
7 CDMRP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507 to request a change in designation.

8 All pre-proposal/pre-application components must be submitted by the applicant through eBRAP  
9 (<https://eBRAP.org/>). Because the invitation to submit a proposal/application is based on the  
10 contents of the pre-proposal/pre-application, applicants should not change the title or research  
11 objectives after the pre-proposal/pre-application is submitted.

12 Applicants and organizations identified in the pre-proposal/pre-application should be the same as  
13 those intended for the subsequent proposal/application submission. If any changes are necessary  
14 after submission of the pre-proposal/pre-application, the applicant must contact the CDMRP  
15 Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507.

16 Applicants with an ORCID identifier should enter that information in the appropriate field in the  
17 “My Profile” tab in the “Account Information” section of eBRAP.

18 The pre-proposal/pre-application consists of the following components, which are organized in  
19 eBRAP by separate tabs (refer to the General Submission Instructions, Section II.B, for  
20 additional information on pre-application submission):

21 • **Tab 1 – Application Information**

22 Submission of proposal/application information includes assignment of primary and  
23 secondary research classification codes, which may be found at  
24 <https://ebrap.org/eBRAP/public/Program.htm>. Note that the codes have recently been  
25 revised. Applicants are strongly encouraged to review and confirm the codes prior to making  
26 their selection.

27 • **Tab 2 – Application Contact**

28 Enter contact information for the PI. Enter the organization’s Business Official responsible  
29 for sponsored program administration (the “person to be contacted on matters involving this  
30 application” in Block 5 of the Grants.gov SF424 Form). The Business Official must either  
31 be selected from the eBRAP list or invited for the pre-proposal/pre-application to be  
32 submitted.

33 Select the performing organization (site at which the PI will perform the proposed work) and  
34 the contracting organization (organization submitting on behalf of the PI, which corresponds  
35 to Block 5 on the Grants.gov SF424 (R&R) Form), and click on “Add Organizations to this  
36 Pre-application.” The organization(s) must be either selected from the eBRAP drop-down  
37 list or invited in order for the pre-proposal/pre-application to be submitted.

1 It is recommended that an Alternate Submitter is identified in the event that assistance with  
2 pre-proposal/pre-application submission is needed.

3 • **Tab 3 – Collaborators and Key Personnel**

4 Enter the name, organization, and role of all collaborators and key personnel associated with  
5 the pre-proposal/pre-application.

6 [FY18 JPC-1/MSIS Medical Simulation and Training Technologies Steering Committee](#)  
7 [members](#) should not be involved in any pre-proposal/pre-application or proposal/application  
8 including, but not limited, to concept design, proposal/application development, budget  
9 preparation, and the development of any supporting documentation. For questions related to  
10 the Steering Committee members and pre-proposals/pre-applications or  
11 proposals/applications, refer to [Section II.H.2.c, Withdrawal](#), or contact the CDMRP Help  
12 Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507.

13 To preserve the integrity of its peer and programmatic review processes, the CDMRP  
14 discourages inclusion of any employee of its review contractors having any role in  
15 proposal/application preparation, research, or other duties for submitted proposals/  
16 applications. For FY18, the identity of the peer review contractor may be found at the  
17 CDMRP website (<http://cdmrp.army.mil/about/2tierRevProcess.shtml>). The programmatic  
18 review is performed by the FY18 JPC-1.MSIS Medical Simulation and Training  
19 Technologies Steering Committee. Pre-proposals/Pre-applications or proposals/applications  
20 that include names of personnel from either of these companies will be administratively  
21 withdrawn unless plans to manage conflicts of interest (COIs) are provided and deemed  
22 appropriate by the Government. Refer to the General Submission Instructions, Appendix 1,  
23 for detailed information.

24 • **Tab 4 – Conflicts of Interest**

25 List all individuals other than collaborators and key personnel who may have a COI in the  
26 review of the pre-proposal/pre-application (including those with whom the PI has a personal  
27 or professional relationship).

28 Federal agency personnel involved in the review process and/or with making funding  
29 recommendations are prohibited from being involved in the research proposed or assisting in  
30 any pre-proposal/pre-application, including, but not limited to, concept design,  
31 proposal/application development, budget preparation, and the development of any  
32 supporting documentation. *If formal collaboration with Military Facility personnel is  
33 planned (i.e., included in the proposal/application in performance of the research), this  
34 prohibition is not applicable. Military Facility is defined as Military Health System (MHS)  
35 facility, research laboratory, medical treatment facility, dental treatment facility, or a DoD  
36 activity embedded with a civilian medical center. However, these Military Facility  
37 personnel cannot be involved in the review process and/or with making funding  
38 recommendations.*

1 Refer to the General Submission Instructions, Appendix 3, for additional information. For  
2 questions related to COI, contact the CDMRP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or  
3 301-682-5507.

4 • **Tab 5 – Pre-Application Files**

5 ***NOTE: Upload documents as individual PDF files unless otherwise noted. eBRAP will***  
6 ***not allow a file to be uploaded if the number of pages exceeds the limit specified below.***

7 **Pre-Proposal/Pre-Application Narrative (eight-page limit):** The Pre-Proposal/  
8 Pre-Application Narrative page limit applies to text and non-text components (e.g., figures,  
9 tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the  
10 project. Inclusion of URLs that provide additional information to expand the Pre-Proposal/  
11 Pre-Application Narrative and could confer an unfair competitive advantage is prohibited and  
12 may result in administrative withdrawal of the pre-application.

13 The Pre-Proposal/Pre-Application Narrative should include the following:

- 14 ○ **Problem to Be Studied:** Describe the perceived issue(s) and the problems to be studied.  
15 This section should serve as an abstract of the proposed work.
- 16 ○ **Background/Rationale:** Clearly present the ideas and reasoning behind the proposed  
17 research. Include relevant literature citations, preliminary and/or pilot data, and/or other  
18 evidence that led to the development of the proposed research. Any preliminary data  
19 should be from the laboratory of the PI or member(s) of the collaborating team. Briefly,  
20 describe how the proposed work and research will support how to increase performance  
21 through stressful simulation.
- 22 ○ **Hypothesis/Objective and Specific Aims:** State the proposed project’s hypothesis  
23 and/or objectives and the specific aims/tasks of the proposed research.
- 24 ○ **Approach/Methodology:** Describe the research approach and development plan.  
25 Include research design, methods, and analysis/evaluation strategies as well as materials  
26 anticipated to be used during the research. Provide a list of methods planned to be used  
27 in the test and evaluation study that will provide the data/information needed to answer  
28 research questions or successfully complete aims of study. Include in the pre-proposal/  
29 pre-application any relevant procedures/skills anticipated to be included in the proof-of-  
30 concept. If applicable, include a description of human use in the proposed project. For  
31 studies involving human subjects, include a description of the size, characteristics, and  
32 partnering organizations of the subject population that will be employed.
- 33 ○ **Significance, Relevance, and Innovation of the Proposed Effort**
  - 34 – **Significance and Relevance:** Clearly articulate, using a theoretical construct, how  
35 the proposed research and development are relevant to the goal of developing a proof-  
36 of-concept preparation interoperable component that would appropriately support  
37 assessing performance gains after stress-inducing simulation. The proposed design

- 1 needs to address the long-term goals mentioned in this BAA within the proposed  
2 model design/architecture.
- 3 – **Innovation:** Explain how the proposed project is innovative and not an incremental  
4 advancement of previous work and has the potential to improve current practices and  
5 patient outcomes and decrease medical errors.
- 6 ○ **Proposed Study Design/Plan:** Describe the proposed pilot study to demonstrate  
7 effectiveness and efficiency of the TRIAGE proof-of-concept, preferably to be conducted  
8 by a subawardee not involved in the development of the model. Provide the intended  
9 research methodology that will support the pilot study. If applicable, provide preliminary  
10 information such as anticipated type of recruits, number of recruits, control group,  
11 anticipated assessment criteria, inter-rater reliability, and statistical approaches. Refer to  
12 [Section II.A, Program Description](#) for additional information on the research areas of  
13 interest for this BAA.
- 14 ○ **Military Impact:** Describe the anticipated short- and/or long-term outcomes of the  
15 proposed project and their potential impact on improving simulation-based medical  
16 provider training in the MHS. Explain what the potential of this proposed work is for  
17 improving current practices and patient outcomes and decreasing medical errors. Refer  
18 to [Section II.A, Program Description](#) for additional information on the anticipated  
19 outcomes sought by this BAA.
- 20 ○ **Personnel and Facilities:** Describe the role of the PI, co-PIs (if applicable), key  
21 personnel, subawardees (if applicable), and consultants (if applicable) in the research  
22 team, including the expertise each brings to the proposed project. Explain how the  
23 team’s expertise is appropriate and complementary for achieving the research goals.  
24 Also, briefly provide information on the primary facility where the research is expected  
25 to be performed.
- 26 ○ **Open Source/License/Architecture:** Describe the intellectual property that is intended  
27 to be incorporated within the design/plan of the proposed model and identify any  
28 additional costs, such as licensing, that may be needed to ensure flexibility or adaptation  
29 of the research project for Government use. Additionally, provide what is intended to be  
30 open source/architecture within the proposed proof-of-concept.
- 31 ○ **Pre-Proposal/Pre-Application Supporting Documentation:** The items to be included  
32 as supporting documentation for the pre-proposal/pre-application *must be uploaded as*  
33 *individual files* and are limited to the following:
- 34 – **References Cited (one-page limit):** List the references cited (including URLs if  
35 available) in the Pre-Proposal/Pre-Application Narrative using a standard reference  
36 format that includes the full citation (i.e., author[s], year published, title of reference,  
37 source of reference, volume, chapter, page numbers, and publisher, as appropriate).  
38 Include both military and civilian research in the review of the literature, as  
39 applicable.

- 1 – List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations,  
2 acronyms, and symbols used in the Pre-Proposal/Pre-Application Narrative.
- 3 – PI and Key Personnel Biographical Sketches (six-page limit per individual): Upload  
4 as “Biosketch\_LastName.pdf.” Bold or highlight publications relevant to the  
5 proposed project.
- 6 – Budget Summary: Upload as “BudgetSummary.pdf.” Complete the two-page  
7 Pre-Application Budget Summary Form (available for download in eBRAP) as  
8 instructed.
- 9 – Quad Chart: Upload as “QuadChart.pdf.” Complete the one-page Quad Chart Form  
10 (available for download in eBRAP) as instructed.
- 11 Refer to the General Submission Instructions, Section II.C, for detailed information.

12 • **Tab 6 – Submit Pre-Application**

13 This tab must be completed for the pre-proposal/pre-application to be accepted and  
14 processed.

15 **Pre-Proposal/Pre-Application Screening**

16 **Pre-Proposal/Pre-Application Screening Criteria**

17 All pre-proposals/pre-application will be screened by the FY18 JPC-1/MSIS Medical Simulation  
18 and Training Technologies Steering Committee members to determine technical merit and  
19 relevance to the mission of the DHP, PH/TBIRP, and JPC-1/MSIS. Pre-proposals/  
20 Pre-applications will be screened based on the following criteria:

21 • **Rationale, Scientific Methods, and Research:**

- 22 ○ How well the research approach for accomplishing the specific aims is feasible, will  
23 accomplish the objectives, will provide information on proposed methods and analysis/  
24 evaluation strategies, and is based on sound rationale.
- 25 ○ How well the proposed work and research will support the knowledge research on how to  
26 better understand task performance to assess translational skills and the development of a  
27 translational medical research model.
- 28 ○ How well the research is derived from evidence-based, best-of-class, well-documented,  
29 and/or well-adopted designs.

30 • **Significance, Relevance, and Innovation:**

- 31 ○ How well the proposed research is relevant, innovative, and novel, including whether the  
32 proposed research is duplicative of existing research.

1       ○ How well the proposed research is relevant to the goal of delivering a TRIAGE proof-of-  
2       concept that aligns to the context of this BAA.

3       • **Open Source/License/Architecture:**

4       ○ Whether intellectual property that is proposed for incorporation is located in key areas  
5       within the design/plan that would limit future flexibility or adaptation of a TRIAGE  
6       proof-of-concept model. If applicable, whether the proposed open source/architecture  
7       and locations for incorporation are appropriate.

8       • **Study Design/Plan:**

9       ○ How well the methodology proposed of a TRIAGE proof-of-concept model can be  
10      adjusted to include scenarios relevant to military training.

11      ○ How well the engineering/technical design that will be used to achieve the project goals  
12      demonstrates the feasibility of the proposed TRIAGE proof-of-concept model.

13      • **Military Impact:** How well the project’s anticipated short- and/or long-term outcomes are  
14      relevant to the military in a way that is consistent with the intent of the award mechanism.

15      • **Personnel, Facilities, Timelines, and Budget:** How well the expertise, experience, and  
16      knowledge of the key research personnel (including co-PIs, if applicable), subawardees (if  
17      applicable), and consultants (if applicable) are appropriate and complementary for achieving  
18      the research goals.

19      **Notification of Pre-Proposal/Pre-Application Screening Results**

20      Following the pre-proposal/pre-application screening, applicants will be notified as to whether or  
21      not they are invited to submit proposals/applications; however, they will not receive feedback  
22      (e.g., a critique of strengths and weaknesses) on their pre-proposal/pre-application. The  
23      estimated timeframe for notification of invitation to submit a proposal/application is indicated on  
24      the [Section I, Overview of the Funding Opportunity](#) of this BAA.

25      **II.D.2.b. Step 2: Full Proposal/Application Submission Content**

26      **Proposals/Applications will not be accepted unless the PI has received notification of**  
27      **invitation.**

28      *The CDMRP cannot make allowances/exceptions to its policies for submission problems*  
29      *encountered by the applicant organization using system-to-system interfaces with Grants.gov.*

30      Each proposal/application submission must include the completed full proposal/application  
31      package for this BAA. The full proposal/application package is submitted by the Authorized  
32      Organizational Representative through Grants.gov (<http://www.grants.gov/>) for extramural  
33      organizations or through eBRAP (<https://ebrap.org/>) for intramural organizations. See Table 1  
34      below for more specific guidelines.

1 **II.D.2.b.i. Full Proposal/Application Guidelines**

2 Extramural organizations must submit full proposals/applications through Grants.gov.  
 3 Applicants must create a Grants.gov Workspace for submission, which allows the  
 4 proposal/application components to be completed online and routed through the applicant  
 5 organization for review prior to submission. Applicants may choose to download and save  
 6 individual PDF forms rather than filling out webforms in the Workspace. A compatible version  
 7 of Adobe Reader must be used to view, complete, and submit a proposal/application package  
 8 consisting of PDF forms. If more than one person is entering text into a proposal/application  
 9 package, the same version of Adobe Reader software should be used by each person. Check the  
 10 version number of the Adobe software on each user’s computer to make sure the versions match.  
 11 Using different versions of Adobe Reader may cause submission and/or save errors – even if  
 12 each version is individually compatible with Grants.gov. Refer to the General Submission  
 13 Instructions, Section III, and the “Apply For Grants” page of Grants.gov  
 14 (<https://www.grants.gov/web/grants/applicants/apply-for-grants.html>) for further information  
 15 about the Grants.gov Workspace submission process. Submissions of extramural proposals/  
 16 applications through eBRAP may be withdrawn.

17 **Table 1. Full Proposal/Application Submission Guidelines**

<b>Proposal/Application Package Location</b>
Download proposal/application package components for W81XWH-18-MSISRP-MSI1 from Grants.gov ( <a href="http://www.grants.gov">http://www.grants.gov</a> ) and create a Grants.gov Workspace. The Workspace allows online completion of the proposal/application components and routing of the proposal/application package through the applicant organization for review prior to submission.
<b>Full Proposal/Application Package Components</b>
<b>SF424 (R&amp;R) Application for Federal Assistance Form:</b> Refer to the General Submission Instructions, Section III.A.1, for detailed information.
Descriptions of each required file can be found under Full Proposal/Application Submission Components: <ul style="list-style-type: none"> <li>• <a href="#">Attachments</a></li> <li>• <a href="#">Research &amp; Related Personal Data</a></li> <li>• <a href="#">Research &amp; Related Senior/Key Person Profile (Expanded)</a></li> <li>• <a href="#">Research &amp; Related Budget</a></li> <li>• <a href="#">Project/Performance Site Location(s) Form</a></li> <li>• <a href="#">R&amp;R Subaward Budget Attachment(s) Form</a> (if applicable)</li> </ul>

### Proposal/Application Package Submission

#### **Create a Grants.gov Workspace.**

Add participants (applicants and Business Officials) to the Workspace, complete all required forms, and check for errors before submission.

#### **Submit a Grants.gov Workspace Package.**

A proposal/application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the proposal/application package **at least 24-48 hours prior to the close date** to allow time to correct any potential technical issues that may disrupt the proposal/application submission.

Note: If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget needs to be modified, an updated Grants.gov proposal/application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the proposal/application submission deadline.

### Proposal/Application Verification Period

The full proposal/application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the proposal/application verification period. During the proposal/application verification period, the full proposal/application package, *with the exception of the Project Narrative and Budget Form*, may be modified.

### Further Information

#### **Tracking a Grants.gov Workspace Package.**

After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission. Refer to the General Submission Instructions, Section III, for further information regarding Grants.gov requirements.

1  
2 Proposal/Application viewing, modification, and verification in eBRAP are strongly  
3 recommended, but not required. ***The Project Narrative and Budget cannot be changed after***  
4 ***the proposal/application submission deadline.*** Prior to the full proposal/application deadline, a  
5 corrected or modified full proposal/application package may be submitted. Other proposal/  
6 application components may be changed until the end of the proposal/application verification  
7 period. Verify that subaward budget(s) and budget justification forms are present in eBRAP  
8 during the proposal/application verification period. If these components are missing, upload  
9 them to eBRAP before the end of the proposal/application verification period. After the end of  
10 the proposal/application verification period, the full proposal/application cannot be modified.

11 ***Material submitted after the end of the proposal/application verification period, unless***  
12 ***specifically requested by the Government, will not be forwarded for processing.***

13 The full proposal/application package must be submitted using the unique eBRAP log number to  
14 avoid delays in proposal/application processing.

1 **II.D.2.b.ii Full Proposal/Application Submission Components**

2 The Grants.gov submission package includes the following components (refer to the General  
3 Submission Instructions, Section III, for additional information on proposal/application  
4 submission).

- 5 • **SF424 (R&R) Application for Federal Assistance Form:** Refer to the General Submission  
6 Instructions, Section III, for detailed information.

7 **Attachments:**

8 *Each attachment to the full proposal/application components must be uploaded as an*  
9 *individual file in the format specified and in accordance with the formatting guidelines*  
10 *listed in the General Submission Instructions, Appendix 4.*

11 For all attachments, ensure that the file names are consistent with the guidance. Attachments  
12 will be rejected if the file names are longer than 50 characters or if they have incorrect file  
13 names, i.e., containing characters other than the following: A-Z, a-z, 0-9, underscore,  
14 hyphen, space, and period. In addition, there are file size limits that may apply in some  
15 circumstances. Individual attachments may not exceed 20 MB and the file size for the entire  
16 full submission package may not exceed 200 MB.

- 17 ○ **Attachment 1: Project Narrative (20-page limit):** Upload as “ProjectNarrative.pdf.”  
18 There is no form for this information. The attachments must be PDF files in accordance  
19 with the formatting guidelines specified for full proposal/application preparation.  
20 Inclusion of URLs that provide additional information to expand the Project Narrative  
21 and could confer an unfair competitive advantage is prohibited and will result in  
22 administrative withdrawal of the proposal/application.

23 A detailed description of the research to be undertaken should be submitted. This should  
24 include the areas provided below and address their relationship to the state of knowledge  
25 in the field and to comparable work in progress elsewhere. Evaluation of the proposed  
26 research will be influenced by the adequacy of this information.

27 The following general outline should be followed:

- 28 – **Background:** Present theoretical framework behind the proposed research; include  
29 relevant literature citations or preliminary data on the proposed methodologies.  
30 Additionally, present the ideas, reasoning, justification, and stakeholder needs that  
31 will influence the design and development of the proposed TRIAGE proof-of-concept  
32 model and identify the data-driven information used to support the proposed TRIAGE  
33 proof-of-concept model. Describe how the proposed work and research will support  
34 the knowledge research on how to increase performance through stressful simulation.  
35 Describe previous experience most pertinent to this project. Any preliminary data  
36 should be from the laboratory of the PI or member(s) of the collaborating team.
- 37 – **Hypotheses/Objectives:** State the hypotheses or research/evaluation questions and  
38 overall objective(s) to be reached.

- 1       – **Specific Aims:** Concisely explain the project’s specific aims to include expected  
2       timeframe of each aim. If this proposal/application is part of a larger study, present  
3       only tasks this award would fund. Describe how the research approach for  
4       accomplishing the specific aims is feasible, will accomplish the proposed objectives,  
5       will provide information on proposed methods and analysis/evaluation strategies, and  
6       is based on sound rationale.
- 7       – **Project Design:** Describe and define the experimental design, methods, and analyses  
8       in sufficient detail for evaluation.
- 9       ▪ Identify and describe the hypothesis or research question(s) to be studied and the  
10      projected outcome(s) of the proposed research.
- 11      ▪ State the virtual gaming platform used for the preparation of the interoperable  
12      component.
- 13      ▪ Provide the proposed procedures/skills that are anticipated to be included in the  
14      proof-of-concept. Explain why the proposed procedures/skills align with the  
15      proposed methodology, and describe those components of the proposed  
16      procedures/skills that would be difficult to integrate into the proof-of-concept.
- 17      ▪ Provide a detailed process, including but not limited to, proposed methodology on  
18      how the proposed TRIAGE proof-of-concept will be tested and evaluated to  
19      demonstrate that the concept could support the items listed in this BAA as well as  
20      potentially supporting the future needs. Include separate test and evaluation plans  
21      applicable for software and hardware approaches.
- 22      ▪ Provide a detailed protocol, including, but not limited to, proposed  
23      methodologies, type of recruits, recruitment numbers, anticipated dropout rate,  
24      assessment criteria, inter-rater reliability, intended medical domain(s) or  
25      discipline(s), control groups, and defined statistical models, if applicable. Explain  
26      how the known, and even unanticipated unknown, variables will be addressed.
- 27      ▪ Define the study variables (independent/dependent) and define how they will be  
28      measured. Include a description of appropriate controls and the endpoints to be  
29      tested. Describe how data will be collected and analyzed in a manner that is  
30      consistent with the study objectives. Describe the measurement tools and provide  
31      definitions as well as the tolerance ranges that the tools are designed to measure.
- 32      ▪ For development of devices and technologies, discuss the engineering/technical  
33      design that will be used to achieve the project goals, demonstrating the feasibility  
34      of the proposed product development. Describe end user context need and how  
35      feedback will allow device/technology to be intuitive to the end user. Discuss the  
36      perceived engineering/design strengths and flaws and recommendations for  
37      overcoming/preventing them.
- 38      ▪ Address all potential risks/barriers and provide plans for addressing potential  
39      delays and unexpected events. Provide a risk management plan to address

1 barriers to plans with objective, easily and independently measured metrics for  
2 Cost, Schedule, and Performance. As relevant, describe plans for addressing  
3 potential issues unique to working within the MHS.

- 4 ▪ Document the availability and accessibility of the study materials (including data)  
5 needed as applicable.

- 6 – **Additional Information:** If human subjects are included in the research,  
7 proposals/applications may be submitted without human use protocols and  
8 institutional approvals. However, protocols with required institutional approvals  
9 must be submitted for approval no later than 60 days after award to demonstrate  
10 continued progress and ensure continuation of payment. The Contracting or Grants  
11 Officer may make exceptions in situations where human use is not expected to begin  
12 until after the first year of the research project. In such cases, a timeframe for  
13 submission of the appropriate protocols and institutional approvals will be established  
14 prior to award.

15 *Applicants and collaborating organizations may not use, employ, or subcontract for the*  
16 *use of any human participants, including the use of human anatomical substances,*  
17 *human data, and/or human cadavers until applicable regulatory documents are*  
18 *reviewed and approved by the USAMRMC ORP to ensure that DoD regulations have*  
19 *been met.*

- 20 ○ **Attachment 2: Supporting Documentation:** Combine and upload as a single file  
21 named “Support.pdf.” Start each document on a new page. If documents are scanned to  
22 PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting  
23 Documentation attachment should not include additional information such as figures,  
24 tables, graphs, photographs, diagrams, chemical structures, or drawings. These items  
25 should be included in the Project Narrative.

26 *There are no page limits for any of these components unless otherwise noted. Include*  
27 *only those components described below; inclusion of items not requested or viewed as*  
28 *an extension of the Project Narrative will result in the removal of those items or may*  
29 *result in administrative withdrawal of the proposal/application.*

- 30 – **References Cited:** List the references cited (including URLs, if available) in the  
31 Project Narrative using a standard reference format that includes the full citation (i.e.,  
32 author[s], year published, title of reference, source of reference, volume, chapter,  
33 page numbers, and publisher, as appropriate).

- 34 – **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations,  
35 acronyms, and symbols.

- 36 – **Facilities, Existing Equipment, and Other Resources:** Describe the facilities and  
37 equipment available for performance of the proposed project and any additional  
38 facilities or equipment proposed for acquisition at no cost to the award. Indicate  
39 whether or not Government-furnished facilities or equipment are proposed for use.  
40 If so, reference should be made to the original or present Government award under

- 1 which the facilities or equipment items are now accountable. There is no form for  
2 this information.
- 3 – Publications and/or Patent Abstracts (five-document limit): Include a list of relevant  
4 publication URLs and/or patent abstracts. If publications are not publicly available,  
5 then copies of up to five published manuscripts may be included in Attachment 2.  
6 Extra items will not be reviewed.
- 7 – Letters of Organizational Support: Provide a letter (or letters, if applicable), signed  
8 by the Department Chair or appropriate organization official, confirming the  
9 laboratory space, equipment, and other resources available for the project. Letters of  
10 support not requested in the BAA, such as those from members of Congress, do not  
11 impact proposal/application review or funding decisions.
- 12 – Letters of Collaboration (if applicable): Provide a signed letter from each  
13 collaborating individual or organization that will demonstrate that the PI has the  
14 support or resources necessary for the proposed work. If an investigator at an  
15 intramural organization is named as a collaborator on a proposal/application  
16 submitted through an extramural organization, the proposal/application must include  
17 a letter from the collaborator’s Commander or Commanding Officer at the intramural  
18 organization that authorizes the collaborator’s involvement.
- 19 – Intellectual Property: Information can be found in Code of Federal Regulations,  
20 Title 2, Part 200.315 (2 CFR 200.315), “Intangible Property.”
- 21 ▪ An appropriate justification for incorporating proprietary tools *must* be included.  
22 ***Proposed proprietary intellectual property components must be clearly and***  
23 ***legibly marked in the full proposal/application. Failure to clearly and legibly***  
24 ***list, describe, justify, and mark proprietary property will result in full forfeiture***  
25 ***of any and all proprietary claims.***
- 26 ▪ Open source and open architecture components must be highlighted.  
27 Proposals/Applications must fully demonstrate that all necessary permissions  
28 have been obtained from any third parties.
- 29 ▪ Intellectual and Material Property Plan (if applicable): Provide a plan for  
30 resolving intellectual and material property issues among participating  
31 organizations.
- 32 ▪ Intangible property acquired, created, or developed under this award will be  
33 subject to all rights and responsibilities established at 2 CFR 200.315. Should the  
34 applicant intend to use, in the performance of this program, pre-existing, legally  
35 protected and perfected intangible property and for which no Federal funds had  
36 been used in the development of said property, the applicant must:
- 37 ❖ Clearly identify all such property; and

- 1                   ❖ Identify the cost to the Federal Government for use or license of such  
2                   property, if applicable;
- 3                   ▪ Describe how the proposed task performance assessment tool incorporates open  
4                   source/license/architecture and intellectual property components available for  
5                   license. Indicate where in the proof-of-concept or the design the respective  
6                   proprietary or open source/architecture components are located.
- 7                   – **Use of DoD Resources (if applicable):** Provide a letter of support signed by the  
8                   lowest-ranking person with approval authority confirming access to active duty  
9                   military patient populations and/or DoD resources or databases.
- 10                  – **Use of VA Resources (if applicable):** Provide a letter of support from the VA  
11                  Facility Director(s) or individual designated by the VA Facility Director(s), such as  
12                  the ACOS/R&D or Clinical Service Chief confirming access to VA patients,  
13                  resources, and/or VA research space. For VA applicants, if the VA NPC is not  
14                  identified as the applicant institution for administering the funds, include a letter from  
15                  the VA ACOS/R&D confirming this arrangement and identifying the institution that  
16                  will administer the funds associated with the proposed research.
- 17                  – *If the project involves collaboration with a Military Facility, special requirements*  
18                  *apply.* A DoD researcher, to include collaborating DoD applicants, must obtain a  
19                  letter from his/her commanding officer or Military Facility director authorizing  
20                  his/her participation in the research project. This letter must be included with the  
21                  proposal/application.
- 22                  – Joint Sponsorship: Describe present or prospective joint sponsorship of any portion  
23                  of the program outlined in the proposal/application. In the absence of agreements  
24                  among sponsors for joint support, the proposal/application should be structured so  
25                  that the research can be carried out without the resources of any other sponsor. If,  
26                  however, it is desirable to request partial support from another agency, the proposed  
27                  plan should be stated and the reasons documented. If the plan cannot be formulated  
28                  at the time the proposal/application is submitted, information should be sent later as  
29                  an addendum to the proposal/application. Prior approval from each organization must  
30                  be secured for research to be undertaken under joint sponsorship. Provide letters of  
31                  support related to recruitment, subject access, and data access plans.
- 32                  ○ **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf.” The  
33                  technical abstract is used by all reviewers. Abstracts of all funded research projects will  
34                  be posted publicly. ***Do not include proprietary or confidential information.*** Use only  
35                  characters available on a standard QWERTY keyboard. Spell out all Greek letters, other  
36                  non-English letters, and symbols. Graphics are not allowed.
- 37                  The structured technical abstract should be clear and concise and, at a minimum, provide  
38                  the following information:
- 39                  – Background: Provide a brief statement of the ideas and theoretical reasoning behind  
40                  the proposed work.

- 1 – Objective/Hypothesis: State the objective to be reached/hypothesis to be tested.  
2 Provide evidence or rationale that supports the objective/hypothesis.
- 3 – Specific Aims: State concisely the specific aims of the study.
- 4 – Study Design: Briefly describe the study design.
- 5 – Relevance: Provide a brief statement explaining the potential relevance of the  
6 proposed work to addressing the intent of this BAA, which is a gaming interoperable  
7 component that elicits cognitively demanding problem-solving and decision-making  
8 under high-stress scenarios in order to increase performance, adaptability, and agility  
9 that also translates to real-world scenarios.
- 10 ○ **Attachment 4: Lay Abstract (one-page limit):** Upload as “LayAbs.pdf.” The lay  
11 abstract is used by all reviewers. Abstracts of all funded research projects will be posted  
12 publicly. *Do not include proprietary or confidential information.* Use only characters  
13 available on a standard QWERTY keyboard. Spell out all Greek letters, other non-  
14 English letters, and symbols. Graphics are not allowed.
- 15 Lay abstracts should be written using the outline below. Do not duplicate the technical  
16 abstract.
- 17 – Clearly describe the objectives and theoretical reasoning behind the proposed work in  
18 a manner readily understood by readers without a background in science or medicine.
- 19 – Clearly describe the problem or question to be addressed and the ultimate  
20 applicability and impact of the research.
- 21 ▪ What types of patients will it help, and how will it help them? Include the current  
22 available statistics to the related injury/condition.
- 23 ▪ What are the potential clinical applications, benefits, and risks?
- 24 ▪ What is the projected timeline it may take to achieve the expected patient-related  
25 outcome?
- 26 ▪ Describe how the proposed project will benefit Service members, Veterans,  
27 and/or their family members.
- 28 ○ **Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as “SOW.pdf.”  
29 The suggested SOW format and examples specific to different types of research projects  
30 are available on the eBRAP “Funding Opportunities & Forms” web page  
31 (<https://ebrap.org/eBRAP/public/Program.htm>). For the FY18 PH/TBIRP TRIAGE  
32 Award mechanism, use the SOW format example titled “SOW (Statement of Work)  
33 Generic Format” or “SOW for Clinical Research (Including Trials, Special Populations),”  
34 as appropriate. Include a Gantt chart depicting project schedule timeline, including  
35 objectives that must be accomplished in order for the project to be successful. The SOW

1 must be in PDF format prior to attaching. Refer to the General Submission Instructions,  
2 Section II.C.2, for detailed guidance on creating the SOW.

3 – For studies with prospective accrual of human subjects, indicate quarterly enrollment  
4 targets.

5 – For use of human anatomical substances, identify the commercial or organizational  
6 source(s) of the material. For cell lines, identify cell line(s) to be used. If human  
7 anatomical substances (including cell lines) will be used, specify whether or not  
8 identifiable information is accessible to the research team by any means.

9 – If applicable, indicate time required for submission and/or approval of documents  
10 (e.g., Investigational New Drug and Investigational Device Exemption) to the U.S  
11 Food and Drug Administration (FDA) or appropriate Government regulatory agency.

12 – For studies involving human subjects, allow at least 2 to 3 months for regulatory  
13 review and approval by the USAMRMC HRPO; this does not include the additional  
14 time required for local IRB review and approval, as stated above.

15 – Refer to the General Submission Instructions, Appendix 1, for additional regulatory  
16 information.

- 17 ○ **Attachment 6: Impact/Outcomes Statement (one-page limit):** Upload as  
18 “Impact.pdf.” Explain the potential impact of the research in the field, the significance of  
19 this impact, and when it can be anticipated. Explain how the results of this research are  
20 expected to impact the intended beneficiaries. Expand upon the dual (military and  
21 public) purpose for the research, as appropriate.

22 – **Short-Term Impact:** Describe the anticipated outcome(s)/results(s)/theoretical  
23 framework, design, and/or plan that will be directly attributed to the results of the  
24 proposed research.

25 – **Long-Term Impact:** Describe the anticipated long-term clinical/patient gains or  
26 commercial end product from the proposed project. Explain how and why the project  
27 outcomes will transform medical provider preparation and education.

28 – **Military Relevance:** Clearly articulate how the proposed project meets the needs of  
29 injured Service members and either allows them to return to duty or resume a fully  
30 active lifestyle in the civilian sector.

31 – **Public Purpose:** If appropriate, provide a concise, detailed description on how this  
32 project will benefit the general public.

- 33 ○ **Attachment 7: Innovation Statement (two-page limit):** Upload as “Innovation.pdf.”  
34 Describe how the proposed project is innovative. Research deemed innovative may  
35 introduce a new paradigm, challenge current paradigms, look at existing problems from  
36 new perspectives, or exhibit other creative qualities. Investigating the next logical step or  
37 incremental advancement on published data is not considered innovative. This may

1 include a proposed conceptual framework, design, and/or plan of key components and  
2 how they integrate/communicate with each other.

- 3 ○ **Attachment 8: Human Subject Recruitment and Safety Procedures (if applicable;  
4 no page limit):** Upload as “HumSubProc.pdf.” The Human Subject Recruitment and  
5 Safety Procedures attachment should include the components listed below.

- 6 – **Study Population:** Describe the target population (to whom the study findings will  
7 be generalized) and the nature, approximate number, and pertinent demographic  
8 characteristics of the accessible population at the study site (population from whom  
9 the sample will be recruited/drawn). Demonstrate that the research team has access to  
10 the proposed study population. Furthermore, discuss past efforts in recruiting human  
11 subjects from the target population for previous studies (if applicable). Address any  
12 potential barriers to accrual and plans for addressing unanticipated delays. Include  
13 justification of any age, race, ethnicity, or sex limitations provided. *For studies  
14 proposing to include military personnel as volunteers, refer to the General  
15 Submission Instructions, Appendix 1, for more information.*

- 16 – **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the  
17 proposed study. Inclusion/Exclusion criteria should take into consideration the  
18 specific risk profile of the studies to be conducted. Provide detailed justification for  
19 exclusions.

20 ***Inclusion of Women and Minorities in Study.*** Consistent with the Belmont Report,  
21 “Ethical Principles and Guidelines for the Protection of Human Subjects,” and  
22 Congressional legislation, special attention is given to inclusion of women and/or  
23 minorities in studies funded or supported by the USAMRMC. This policy is intended  
24 to promote equity both in assuming the burdens and in receiving the benefits of  
25 human subjects’ research. Include an appropriate justification if women and/or  
26 minorities will be excluded from the study.

- 27 – **Description of the Recruitment Process:** Explain methods for identification of  
28 potential human subjects (e.g., medical record review, obtaining sampling lists, and  
29 health care provider identification).

- 30 ▪ Describe the recruitment process in detail. Address who will identify potential  
31 human subjects, who will recruit them, and what methods will be used to recruit  
32 them.

- 33 ▪ Include a detailed description of and justification for the compensation plan if the  
34 human subjects will be compensated for participation in the study.

- 35 ▪ Describe the recruitment and advertisement materials. The recruitment materials  
36 should not be coercive or offer undue inducements and should accurately reflect  
37 the study.

- 1 – **Description of the Informed Consent Process:** Specifically describe the plan for  
2 obtaining informed consent from human subjects.

3 *For the proposed study, provide a draft, in English, of the Informed Consent Form.*

- 4 ▪ Identify who is responsible for explaining the study, answering questions, and  
5 obtaining informed consent. Include a plan for ensuring that human subjects’  
6 questions will be addressed during the consent process and throughout the study.
- 7 ▪ Include information regarding the timing and location of the consent process.
- 8 ▪ Address issues relevant to the mental capacity of the potential human subject  
9 (e.g., altered capacity due to brain injury, stress/life situations, human subject age,  
10 or administration of any mind-altering substances such as tranquilizers, conscious  
11 sedation or anesthesia), if applicable.
- 12 ▪ Address how privacy and time for decision-making will be provided and whether  
13 or not the potential human subject will be allowed to discuss the study with  
14 anyone before making a decision.
- 15 ▪ Consider the need for obtaining ongoing consent or for re-assessing capacity over  
16 the course of a long-term study and describe any relevant procedures to assure  
17 continued consent.
- 18 ▪ Describe the plan for the consent of the individual’s Legally Authorized  
19 Representative (LAR) to be obtained prior to the human subject’s participation in  
20 the study. State law defines who may act as the LAR. The local IRB/EC of  
21 record should be consulted for guidance regarding who can serve as LAR for  
22 research at the study site. Note: The PI must describe a clear intent to benefit for  
23 human subjects who cannot give their own consent to participate in the proposed  
24 study to be in compliance with 10 USC 980  
25 ([http://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-  
27 title10-subtitleA-partII-chap49-sec980.pdf](http://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-<br/>26 title10-subtitleA-partII-chap49-sec980.pdf)). If applicable, refer to the General  
Submission Instructions, Appendix 1, for more information.
- 28 ▪ Assent: If minors or other populations that cannot provide informed consent are  
29 included in the proposed study, a plan to obtain assent (agreement) from those  
30 with capacity to provide it, or a justification for a waiver of assent, should be  
31 provided. Applicants should consult with their local IRB/EC to identify the  
32 conditions necessary for obtaining assent.

- 33 – **Screening Procedures:** List and describe any evaluations (e.g., laboratory  
34 procedures, history, or physical examination) that are required to determine  
35 eligibility/suitability for study participation. Note that some screening procedures  
36 may require a separate consent or a two-stage consent process. Informed consent  
37 must be obtained prior to initiation of any procedures for the purpose of determining  
38 eligibility.

- 1           – **Risks/Benefits Assessment**
- 2           ▪ **Foreseeable risks:** Clearly identify all study risks. Study risks include any risks
- 3           that the human subject is subjected to as a result of participation in the study.
- 4           Consider psychological, legal, social, and economic risks as well as physical
- 5           risks. If the risks are unknown, this should be stated. If applicable, any potential
- 6           risk to the study personnel should be identified.
- 7           ▪ **Risk management and emergency response**
- 8           ❖ Describe how safety surveillance and reporting to the IRB and FDA (if
- 9           applicable) will be managed and conducted.
- 10          ❖ Describe all safety measures to minimize and/or eliminate risks to human
- 11          subjects and study personnel or to manage unpreventable risks. Include
- 12          safeguards and planned responses such as dose reduction or stopping criteria
- 13          based on toxicity grading scales or other predetermined alert values.
- 14          ❖ Discuss the overall plan for provision of emergency care or treatment for an
- 15          adverse event for study-related injuries, to include who will be responsible for
- 16          the cost of such care.
- 17          ❖ Address any special precautions to be taken by the human subjects before,
- 18          during, and after the study (e.g., medication washout periods, dietary
- 19          restrictions, hydration, fasting, and pregnancy prevention).
- 20          ❖ Describe any special care (e.g., wound dressing assistance, transportation due
- 21          to side effects of study intervention impairing ability to drive) or equipment
- 22          (e.g., thermometers, telemedicine equipment) needed for human subjects
- 23          enrolled in the study.
- 24          ▪ **Potential benefits:** Describe known and potential benefits of the study to the
- 25          human subject, a specific community, or society. *Note: Payment and/or other*
- 26          *compensation for participation are not considered to be benefits.*
- 27          ○ **Attachment 9: Data Management (no page limit):** Upload as “DataManage.pdf.”
- 28          The Data Management attachment should include the components listed below.
- 29          Describe all methods used for data collection to include the following:
- 30          – **Identifiers:** Describe the unique identifiers or specific code system to be used to
- 31          identify human subjects, if applicable.
- 32          – **Confidentiality:** Explain measures taken to protect the privacy of study human
- 33          subjects and maintain confidentiality of study data. Strategies to protect the privacy
- 34          and confidentiality of study records, particularly those containing identifying
- 35          information, should be addressed.

- 1           ▪ Address who will have access to study records, data, and specimens, including an  
2           acknowledgment that representatives of USAMRMC are eligible to review study  
3           records.
- 4           ▪ Address requirements for reporting sensitive information to state or local  
5           authorities.
- 6           – **Disposition of data:** Describe where data (both electronic and hard copy) will be  
7           stored, who will keep the data, how the data will be stored, and the length of time data  
8           will be stored. For FDA-regulated studies, compliance with 21 CFR 11 is required.
- 9           – **Sharing study results:** In cases where the human subject could possibly benefit  
10          medically or otherwise from the information, explain whether or not the results of  
11          screening and/or study participation will be shared with human subjects or their  
12          primary care provider, to include results from any screening or diagnostic tests  
13          performed as part of the study.
- 14          ○ **Attachment 10: Post-Award Project Transition Plan (three-page limit):** Upload as  
15          “Transition.pdf.” Provide information on the methods and strategies proposed to move  
16          the product or knowledge outcomes to the next project phase of studies,  
17          commercialization, and/or delivery to the civilian or military market after successful  
18          completion of the award. The transition plan should include, as applicable, the  
19          components listed below.
  - 20          – Details of the funding strategy that will be used to bring the outcomes to the next  
21          level of development and/or commercialization (e.g., specific potential industry  
22          partners, specific funding opportunities to be applied for).
  - 23          – For knowledge products, a description of how the knowledge will be further  
24          developed, disseminated, and incorporated into clinical care.
  - 25          – A description of collaborations and other resources that will be used to provide  
26          continuity of development.
  - 27          – A brief schedule and milestones for bringing the outcome(s) to the next phase of  
28          studies, commercialization, and/or delivery to the military or civilian market,  
29          including when it can be anticipated to be transitioned to an industry partner or  
30          approved by the FDA.
  - 31          – A risk analysis for cost, schedule, manufacturability, and sustainability.
- 32          ○ **Attachment 11: Representations:** Upload as “MandatoryReps.pdf.” All extramural  
33          applicants must complete and submit the Required Representations template available on  
34          eBRAP (<https://ebrap.org/eBRAP/public/Program.htm>). For more information, see the  
35          General Submission Instructions, Appendix 5, Section B, Representations.
- 36          ○ **Attachment 12: Collaborating DoD Military Facility Budget Form(s), if applicable:**  
37          Upload as “MFBudget.pdf.” If a Military Facility (MHS facility, research laboratory,

1 medical treatment facility, dental treatment facility, or a DoD activity embedded with a  
2 civilian medical center) will be a collaborator in performance of the project, complete the  
3 DoD Military Facility Budget Form, available for download on the eBRAP “Funding  
4 Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>),  
5 including a budget justification, for each military facility as instructed. The costs per  
6 year should be included on the Grants.gov Research and Related Budget form under  
7 subaward costs. Refer to the General Submission Instructions, Section III.A, for detailed  
8 information.

9 To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC  
10 A§1681 et seq.), the DoD is collecting certain demographic and career information to be able  
11 to assess the success rates of women who are proposed for key roles in proposals/applications  
12 in science, technology, engineering, or mathematics (STEM) disciplines. To enable this  
13 assessment, each proposal/application must include the following forms completed as  
14 indicated.

15 **Research & Related Personal Data:** For extramural submissions (via Grants.gov), refer to  
16 the General Submission Instructions, Section III.A.3, for detailed information.

17 **Research & Related Senior/Key Person Profile (Expanded):** Refer to the General  
18 Submission Instructions, Section III.A.4, for detailed information.

19 ○ PI Biographical Sketch (six-page limit): Upload as “Biosketch\_LastName.pdf.” The  
20 suggested biographical sketch format is available on the “Funding Opportunities &  
21 Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP. The  
22 National Institutes of Health Biographical Sketch may also be used. All biographical  
23 sketches should be submitted in the PDF format that is not editable.

24 ○ PI Previous/Current/Pending Support (no page limit): Upload as  
25 “Support\_LastName.pdf.”

26 ○ Key Personnel Biographical Sketches (six -page limit each): Upload as  
27 “Biosketch\_LastName.pdf.”

28 ○ Key Personnel Previous/Current/Pending Support (no page limit): Upload as  
29 “Support\_LastName.pdf.”

30 **Research & Related Budget:** For extramural submissions (via Grants.gov), refer to the  
31 General Submission Instructions, Section III.A.5 for detailed information.

32 **Budget Justification (no page limit):** Upload as “BudgetJustification.pdf.” The budget  
33 justification for the entire period of performance must be uploaded to the Research & Related  
34 Budget after completion of the budget for Period 1.

35 **Project/Performance Site Location(s) Form:** Refer to the General Submission  
36 Instructions, Section III.A.6, for detailed information.

1 **R & R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General  
2 Submission Instructions, Section III.A.7, for detailed information.

- 3 ○ **Extramural Subaward:** Complete the Research & Related Subaward Budget Form  
4 through Grants.gov. (Refer to the General Submission Instructions, Section III.A, for  
5 detailed information.) Verify subaward budget(s) and budget justification forms are  
6 present in eBRAP during the proposal/application verification period. If these  
7 components are missing, upload them to eBRAP before the end of the proposal/  
8 application verification period.

9 **Intramural DoD Collaborator(s):** Complete the DoD Military Budget Form and upload to  
10 Grants.gov attachment form as Attachment 12. (Refer to the General Submission  
11 Instructions, Section III.A, for detailed information.) Intramural DoD Collaborator(s) costs  
12 per year should be included on the Grants.gov Research and Related Budget form under  
13 subaward costs.

14 **NOTE:** Proposals/Applications from **Federal agencies** must include a **Federal Financial**  
15 **Plan** in their budget justifications. Proposals/Applications from organizations that include  
16 **collaborations with DoD Military Facilities** must comply with special requirements. Refer  
17 to the General Submission Instructions, Section III.A.5, Research & Related Budget, for  
18 detailed information.

### 19 **II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) and System for** 20 **Award Management (SAM)**

21 Applicant organizations and all subrecipient organizations must have a DUNS number to submit  
22 proposals/applications to Grants.gov. The applicant organization must also be registered in the  
23 Entity Management functional area of the SAM with an “Active” status to submit proposals/  
24 applications through the Grants.gov portal. Verify the status of the applicant’s organization’s  
25 Entity registration in SAM well in advance of the proposal/application submission deadline.  
26 Allow 3 to 4 weeks to complete the entire SAM registration process. If an applicant has not fully  
27 complied with the requirements at the time the Federal awarding agency is ready to make a  
28 Federal award, the Federal awarding agency may determine that the applicant is not qualified to  
29 receive a Federal award and use that determination as a basis for making a Federal award to  
30 another applicant. Refer to the General Submission Instructions, Section III, for further  
31 information regarding Grants.gov requirements.

### 32 **II.D.4. Submission Dates and Times**

33 All submission dates and times are indicated on the [Section I, Overview of the Funding](#)  
34 [Opportunity](#) of this BAA. Pre-proposal/Pre-application and proposal/application submissions are  
35 required. The pre-proposal/pre-application and proposal/application submission process should  
36 be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of  
37 these deadlines will result in submission rejection.

## 1 **Applicant Verification of Full Proposal/Application Submission in eBRAP**

2 Following retrieval and processing of the full proposal/application, eBRAP will notify the  
3 organizational representatives and PI by email to log into eBRAP to review, modify, and verify  
4 the full proposal/application submission. eBRAP will validate retrieved files against the specific  
5 BAA requirements, and discrepancies will be noted in both the email and in the “Full  
6 Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. It is the  
7 applicant’s responsibility to review all proposal/application components and ensure proper  
8 ordering as specified in the BAA. *If either the Project Narrative or the budget fails eBRAP*  
9 *validation or needs to be modified, an updated full proposal/application package must be*  
10 *submitted prior to the proposal/application submission deadline.* The Project Narrative and  
11 Budget Form cannot be changed after the proposal/application submission deadline.

12 The full proposal/application package submitted to Grants.gov may be viewed and modified in  
13 eBRAP until the end of the proposal/application verification period. During the proposal/  
14 application verification period, the full proposal/application package, *with the exception of the*  
15 *Project Narrative and Budget Form*, may be modified.

16 **For All Submissions:** Verify that subaward budget(s) with budget justification are present in  
17 eBRAP during the proposal/application verification period. If these components are missing,  
18 upload them to eBRAP before the end of the proposal/application verification period.

### 19 **II.D.5. Intergovernmental Review**

20 This BAA is not subject to Executive Order (EO) 12372, “Intergovernmental Review of Federal  
21 Programs.” The EO provides for state and local government coordination and review of  
22 proposed Federal financial assistance and direct Federal development. The EO allows each state  
23 to designate an entity to perform this function. This coordination and review is not required  
24 under this BAA.

### 25 **II.D.6. Funding Restrictions**

26 **NOTE: Proposals/Applications received in response to both the JPC-1/MSIS TRIAGE Award**  
27 **extramural and intramural BAAs will be evaluated and considered for funding together. The**  
28 **Government reserves the right to fund any combination of extramural and/or intramural**  
29 **proposals/applications.**

30 The JPC-1/MSIS expects to allot approximately **\$2.6M** of the FY18 PH/TBIRP appropriation to  
31 fund up to two TRIAGE Award proposals/applications, depending on the quality and number of  
32 proposals/applications received from extramural organizations and intramural organizations.  
33 Funding of proposals/applications received in response to this BAA is contingent upon the  
34 availability of Federal funds for this program. The funding estimated for this BAA is  
35 approximate and subject to realignment.

- 36 • The maximum period of performance is **18 months**, which includes the testing and  
37 evaluation of the proof-of-concept and the results from the test and evaluation.

- 1 • The anticipated total costs (direct and indirect) budgeted for the entire period of performance  
2 will not exceed **\$1.3M**. If indirect cost rates have been negotiated, indirect costs are to be  
3 budgeted in accordance with the organization’s negotiated rate. No budget will be approved  
4 by the Government exceeding **\$1.3M** total costs or using an indirect rate exceeding the  
5 organization’s negotiated rate.
- 6 • All direct and indirect costs of any subaward, contract, or subcontract must be included in the  
7 total direct costs of the primary award.
- 8 • The applicant may request the entire maximum funding amount for a project that may have a  
9 period of performance less than the maximum **18 months**.

10 For this award mechanism, direct costs must be requested for:

- 11 • Travel costs for the PI to attend an In-Progress Review (IPR) meeting anticipated to be held  
12 near the end of 1-year anniversary of the award at a Government location (to be determined).  
13 For planning purposes, it should be assumed that a 1-day IPR meeting will be held in the  
14 National Capital Area. These travel costs are in addition to those allowed for annual  
15 scientific/technical meetings. All planned travel during the period of performance must be  
16 itemized by trip, in the full proposal/application.

17 May be requested for (not all-inclusive):

- 18 • Salary
- 19 • Research-related subject costs
- 20 • Support for multidisciplinary collaborations
- 21 • Equipment
- 22 • Research supplies
- 23 • Travel between collaborating institutions, including travel to military/Government facilities
- 24 • Travel costs for up to two investigators to attend two scientific/technical meetings in addition  
25 to the required IPR meeting described above

26 Refer to the General Submission Instructions, Section III.A.5, for budget regulations and  
27 instructions for the Research & Related Budget. ***For Federal agencies or organizations***  
28 ***collaborating with Federal organizations, budget restrictions apply as are noted in Section***  
29 ***III.A.5 of the General Submission Instructions.***

30 Funds to be obligated on any award resulting from this funding opportunity will be available for  
31 use for a limited time period based on the fiscal year of the funds. The time is considered when  
32 establishing the award’s period of performance. It is anticipated that awards made from this  
33 funding opportunity will be funded with FY18 funds, which will expire for use on September 30,  
34 2024.

1 **II.D.7. Other Submission Requirements**

2 Refer to the General Submission Instructions, Appendix 4, for detailed formatting guidelines.

3 **II.E. PROPOSAL/APPLICATION REVIEW INFORMATION**

4 **II.E.1. Criteria**

5 **II.E.1.a. Peer Review**

6 **Peer Review:** To determine technical merit, all proposals/applications will be evaluated  
7 according to the following scored criteria, which are listed in decreasing order of importance:

8 • **Theoretical Rationale and Scientific Methods**

- 9 ○ How well the study aims, hypotheses or objectives, experimental design, methods, and  
10 analyses are designed to clearly answer the research questions.
- 11 ○ To what degree the research approach for accomplishing the specific aims is feasible, will  
12 accomplish the objectives, will provide information on proposed methods and  
13 analysis/evaluation strategies, and is based on sound rationale.
- 14 ○ How well the study aims, hypotheses or objectives, experimental design, methods, and  
15 analyses are designed to clearly answer the research questions.
- 16 ○ How well the proposed methodologies, evaluation strategy, type of recruits, recruitment  
17 numbers, anticipated dropout rate, assessment criteria, inter-rater reliability, intended  
18 medical domain(s) (or discipline[s]), control groups, statistical protocols, etc., to support  
19 the pilot study are presented and align with the proposed study outcomes.
- 20 ○ Whether there is evidence of an adequate contingency plan, such as a risk mitigation  
21 plan, to resolve potential delays.
- 22 ○ Whether the proposed timeline is appropriate and tasks outlined in the proposal/  
23 application are logical in their progression.
- 24 ○ To what degree the references cited within the proposal/application support the  
25 background, the proposed methodologies, and/or the proposed pilot study methodologies.

26 • **Relevance, Significance, Innovation, and Impact**

- 27 ○ Whether the proposed work is innovative, including whether the proposed research is  
28 duplicative of existing research.
- 29 ○ To what degree the proposed research is relevant to delivering a proof-of-concept  
30 interoperable component for increasing medical provider performance in high-stress  
31 medical care scenarios.

- 1 ○ To what degree the anticipated short- and long-term outcomes resulting from the  
2 proposed study will contribute to the goal of improving the downstream effects of  
3 medical care; whether beneficial to the patient (e.g., improved patient safety, improved  
4 patient outcomes, improved patient quality of life), detrimental, or neutral (i.e., no  
5 difference) will be analyzed and recorded.

6 • **Open Source/License/Architecture**

- 7 ○ To what degree the proposed task performance assessment tool incorporates open  
8 source/license/architecture and intellectual property components available for license.  
9 Evaluate where in the proof-of-concept or the design the respective proprietary or open  
10 source/architecture components are located.

11 • **Personnel and Facilities**

- 12 ○ How the composition and balance of the research team (including other organization  
13 personnel, subawardees, and consultants, as applicable) are appropriate. Whether MHS  
14 medical providers and facilities are included as collaborators and, if not, how the  
15 proposed personnel and facilities might compare to MHS medical providers and facilities.
- 16 ○ To what degree the PI's and research team's backgrounds and expertise are appropriate  
17 and complementary to accomplishing the proposed work.
- 18 ○ To what degree the levels of effort by the PI and other key personnel are appropriate to  
19 ensuring the success of proposed research.
- 20 ○ To what degree the research environment and the accessibility of institutional resources  
21 support the proposed study (including collaborative arrangements).
- 22 ○ Whether there is evidence for appropriate institutional commitment.

23 In addition, the following unscored criteria will also contribute to the overall evaluation of the  
24 proposal/application:

25 • **Budget**

- 26 ○ Whether the budget is appropriate for the proposed research and within the limitations of  
27 this BAA.
- 28 ○ How well the budget aligns with the proposed timeline and overall deliverables.

29 • **Intellectual Property and Transition Plan**

- 30 ○ If applicable, to what degree the intellectual property plan is appropriate.
- 31 ○ If applicable, to what degree the transition plan is appropriate.

1 • **Proposal/Application Presentation**

- 2 ○ To what extent the writing, clarity, and presentation of the proposal/application  
3 components influence the review.

4 **II.E.1.b. Programmatic Review**

5 To make funding recommendations and select the proposal(s)/application(s) that, individually or  
6 collectively, will best achieve the program objectives, the following criteria are used by  
7 programmatic reviewers:

8 • **Ratings and evaluations of the peer reviewers**

9 • **Open source/license/architecture**

- 10 ○ Whether the proposal/application identifies the anticipated Government rights of the  
11 proposed interoperable component

- 12 ○ To what degree the intellectual property components may limit future flexibility or  
13 adaptation of the tool to meet future Government needs

- 14 ○ Degree of public accessibility of outcomes

15 • **Relevance to the mission of the DHP, PH/TBIRP, and JPC-1/MSIS as evidenced by the  
16 following:**

- 17 ○ Adherence to the intent of the award mechanism to assess a proof-of-concept TRIAGE  
18 model

- 19 ○ Programmatic relevance and significance

- 20 ○ Program portfolio balance

- 21 ○ Relative innovation and impact

22 **II.E.2. Proposal/Application Review and Selection Process**

23 All proposals/applications are evaluated by scientists, clinicians, and consumers in a two-tier  
24 review process. The first tier is peer review of proposals/applications against established criteria  
25 for determining technical merit. Each proposal/application is evaluated for its own merit,  
26 independent of other proposals/applications. The second tier is a programmatic review that  
27 makes recommendations for funding to the Commanding General, USAMRMC, on behalf of the  
28 DHA and the OASD(HA), based on technical merit, the relevance to the mission of the DHP,  
29 JPC-1/MSIS, and the PH/TBIRP, the specific intent of the award mechanism, and to other  
30 specified evaluation criteria in the BAA. Programmatic review is a comparison-based process in  
31 which proposals/applications with scientific and technical merit compete in a common pool. *The  
32 highest-scoring proposals/applications from the first tier of review are not automatically  
33 recommended for funding. Funding recommendations depend on various factors as described*

1 *in [Section II.E.1.b, Programmatic Review](#)*. Additional information about the two-tier process  
2 used by the CDMRP can be found at <http://cdmrp.army.mil/about/fundingprocess>.

3 All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-  
4 based selection process. Panel members sign a statement that proposal/application and  
5 evaluation information will not be disclosed outside the panel. Violations of confidentiality can  
6 result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the  
7 applicant or collaborating organizations are prohibited from contacting persons involved in the  
8 review and approval process to gain protected evaluation information or to influence the  
9 evaluation process. Violations of these prohibitions will result in the administrative withdrawal  
10 of the organization's proposal/application. Violations by panel members or applicants that  
11 compromise the confidentiality of the review and approval process may also result in suspension  
12 or debarment from Federal awards. Furthermore, the unauthorized disclosure of confidential  
13 information of one party to another third party is a crime in accordance with 18 USC 1905.

### 14 **II.E.3. Integrity and Performance Information**

15 Prior to making an award where the Federal share is expected to exceed the simplified  
16 acquisition threshold (currently \$150,000) over the period of performance, the Federal awarding  
17 agency is required to review and consider any information about the applicant that is available in  
18 the Federal Awardee Performance and Integrity Information System (FAPIIS).

19 An applicant, at its option, may review FAPIIS, accessible through SAM, and submit comments  
20 to FAPIIS on any information about itself that a Federal awarding agency previously entered and  
21 is currently available in FAPIIS.

22 The Federal awarding agency will consider any comments by the applicant, in addition to other  
23 information in the designated integrity and performance system, in making a judgment about the  
24 applicant's integrity, business ethics, and record of performance under Federal awards when  
25 determining an organization's qualification prior to award, according to the qualification  
26 standards of the DoDGARs or the FAR.

### 27 **II.E.4. Anticipated Announcement and Federal Award Dates**

28 All proposal/application review dates and times are indicated in [Section I, Overview of the](#)  
29 [Funding Opportunity](#).

30 Each PI and organization will receive email notification of posting of the funding  
31 recommendation in eBRAP. Each PI will receive a peer review summary statement on the  
32 strengths and weaknesses of the proposal/application.

## 33 **II.F. FEDERAL AWARD ADMINISTRATIVE INFORMATION**

### 34 **II.F.1. Federal Award Notices**

35 Awards will be made no later than September 30, 2019. Refer to the General Submission  
36 Instructions, Appendix 2, for additional award administration information.

1 After email notification of proposal/application review results through eBRAP, and if selected  
2 for funding, a representative from the USAMRAA will contact the business official authorized to  
3 negotiate on behalf of the PI's organization.

4 Only an appointed USAMRAA Contracting/Grants Officer may obligate the Government to the  
5 expenditure of funds. No commitment on the part of the Government should be inferred from  
6 discussions with any other individual. The award document signed by the Contracting/Grants  
7 Officer is the official authorizing document.

8 ***Federal Organizations:*** Awards to Federal Government organizations will be executed through  
9 the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document  
10 (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative  
11 approvals. Intramural collaborators are reminded to coordinate receipt and commitment of funds  
12 through their respective Resource Manager/Task Area Manager/Comptroller or equivalent  
13 Business Official.

14 After email notification of proposal/application review results through eBRAP, and if selected  
15 for funding, a representative from the CDMRP will contact the business official authorized to  
16 negotiate on behalf of the PI's organization.

#### 17 **II.F.1.a. PI Changes and Award Transfers**

18 An organizational transfer of an award is discouraged and will be evaluated on a case-by-case  
19 basis and only allowed at the discretion of the Contracting/Grants Officer. Refer to the General  
20 Submission Instructions, Appendix 2, for general information on changes to applicants and  
21 organizational transfers.

22 ***Should the PI of a funded project leave the award organization, both the PI and organization***  
23 ***must contact the USAMRAA as soon as possible to discuss options for continued support of***  
24 ***the research project. Every effort should be made to notify the USAMRAA prior to the PI***  
25 ***leaving the organization.***

#### 26 **II.F.2. Administrative and National Policy Requirements**

27 In-person IPR presentations will be requested. Applicable requirements in the DoDGARs found  
28 in 32 CFR, Chapter 1, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative  
29 agreements resulting from this BAA.

30 Applicable requirements in the FAR, found in 48 CFR, Chapter 1, DFARS, found in 48 CFR  
31 Chapter 2, and AFARS, found in 48 CFR Chapter 51, apply to contracts resulting from this  
32 BAA.

33 Refer to the General Submission Instructions, Appendix 2, for general information regarding  
34 administrative requirements.

35 Refer to the General Submission Instructions, Appendix 5, for general information regarding  
36 national policy requirements.

### 1 **II.F.3. Reporting**

2 Refer to the General Submission Instructions, Appendix 2, Section A, for general information on  
3 reporting requirements. *If there are technical reporting requirement delinquencies for any*  
4 *existing USAMRAA-sponsored awards at the applicant organization, no new awards will be*  
5 *issued to the applicant organization until all delinquent reports have been submitted.*

6 Quarterly and annual technical progress reports and quad charts will be required.

7 • Quarterly quad charts including:

8 ○ Objective, measurable, and easily independently verifiable assessment of metrics to  
9 measure progress regarding project cost, schedule, performance, risk, and opportunity.

10 ○ Risk and opportunity assessment of project cost, schedule, and performance. Risk  
11 assessments will use objective, measurable, and easily independently verifiable metrics;  
12 mitigation plans; triggering event; latest potential successful mitigation date; and impacts  
13 of unmitigated risks. Opportunity assessments will use objective, measurable and easily  
14 independently verifiable metrics; exploitation plans; triggering event; latest potential  
15 successful exploitation; and impact of successful opportunity exploitation.

16 ○ Integrated project Gantt chart with all progress to date, supported by the cost,  
17 performance, risk, and opportunity assessments.

18 ○ Budget chart with burn rate, demonstrating funding expended against time, funds  
19 remaining, and planned expense plan through the rest of the project schedule against  
20 planned milestones.

21 • Quarterly and annual technical reports including the following:

22 ○ Full description of architecture and content of new interoperable component, description  
23 of scenarios developed, results and method of pilot study.

24 ○ A report, document, or list of the terminology and respective definitions used for the  
25 variables, metrics, and evaluation criteria and how they were deconstructed. It must  
26 provide the measuring tools and, if needed, how they were used to obtain the  
27 metric/evaluation criteria. Objective measurements are preferred, but subjective  
28 measurements that have rigorous reliability, repeatability, and robustness will be  
29 considered.

30 ○ Explanation, including definitions and descriptions, of TRIAGE determinants of  
31 performance and agility. A report or document with the information and analyzed data of  
32 the actual postulated variables, metrics, and evaluation criteria.

33 ○ Analyzed pilot study data and the specific aims, methodologies, sample and sample size,  
34 inter-rater reliability, assessment criteria, statistical methods, analyzed results,  
35 conclusions, and potential next-step recommendations.

- 1      ○ Completion of preliminary/pilot empirical evaluation of the developed proof-of-concept;
- 2      ○ A description of the components of the proof-of-concept that are proprietary and ones
- 3      that are open source/open architecture. Explanation of Government rights and/or
- 4      proposed pricing structure to the Government (if applicable).
- 5      ○ Documentation of the translational parameters and the respective definitions (if
- 6      applicable).
- 7      ○ Description of the gaps that were uncovered during this research as it pertains to the
- 8      success or improvement measured and an outline of anticipated next steps or
- 9      recommendations.
- 10     • Yearly IPRs reporting on progress

11 Awards resulting from this BAA will incorporate additional reporting requirements related to  
12 recipient integrity and performance matters. Recipient organizations that have Federal contract,  
13 grant, and cooperative agreement awards with a cumulative total value greater than \$10,000,000  
14 are required to provide information to FAPIIS about certain civil, criminal, and administrative  
15 proceedings that reached final disposition within the most recent 5-year period and that were  
16 connected with performance of a Federal award. Recipients are required to disclose,  
17 semiannually, information about criminal, civil, and administrative proceedings as specified in  
18 the applicable Terms and Conditions (see General Submission Instructions, Appendix III.A).

## 19 **II.G. FEDERAL AWARDING AGENCY CONTACTS**

### 20 **II.G.1. CDMRP Help Desk**

21 Questions related to BAA content or submission requirements as well as questions related to the  
22 submission of the pre-proposal/pre-application through eBRAP should be directed to the  
23 CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET.  
24 Response times may vary depending upon the volume of inquiries.

25      Phone:     301-682-5507

26      Email:     [help@eBRAP.org](mailto:help@eBRAP.org)

### 27 **II.G.2. Grants.gov Contact Center**

28 Questions related to full proposal/application submission through the Grants.gov portal should be  
29 directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week  
30 (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide  
31 technical assistance with Grants.gov submission.

32      Phone:     800-518-4726 (International: 1-606-545-5035)

33      Email:     [support@grants.gov](mailto:support@grants.gov)

1 *Sign up on Grants.gov for “send me change notification emails” by following the link on the*  
2 *Synopsis page for the BAA or by responding to the prompt provided by Grants.gov when first*  
3 *downloading the submission package. If the submission package is updated or changed, the*  
4 *original version of the submission package may not be accepted by Grants.gov.*

## 5 **II.H. OTHER INFORMATION**

### 6 **II.H.1. Administrative Actions**

7 After receipt of pre-proposals/pre-applications or proposals/applications from Grants.gov, the  
8 following administrative actions may occur:

#### 9 **II.H.1.a. Rejection**

10 The following will result in administrative rejection of the pre-proposal/pre-application:

- 11 • Pre-Proposal/Pre-Application Narrative exceeds the page limit.
- 12 • Pre-Proposal/Pre-Application Narrative is missing.

13 The following will result in administrative rejection of the proposal/application:

- 14 • Submissions from intramural applicants to this BAA will be rejected.
- 15 • Submission of a proposal/application for which a letter of invitation was not received.
- 16 • Project Narrative exceeds the page limit.
- 17 • Project Narrative is missing.
- 18 • Budget is missing.
- 19 • For proposals/applications including human subjects, the following may result in  
20 administrative rejection:
  - 21 ○ Human Subject Recruitment and Safety Procedures ([Attachment 8](#)) is missing.

#### 22 **II.H.1.b. Modification**

- 23 • Pages exceeding the specific limits may be removed prior to review for all documents other  
24 than the Pre-Proposal/Pre-Application Narrative and Proposal/Application Project Narrative.
- 25 • Documents not requested may be removed.
- 26 • Following proposal/application submission to Grants.gov, the PI will receive an email  
27 request from eBRAP to review, modify, and verify the proposal/application submitted to  
28 Grants.gov. During this verification period, the PI may upload missing documents  
29 (excluding those listed above, [Section II.H.2.a, Rejection](#)), replace files, and re-categorize  
30 files. These modifications must be completed by the end of the proposal/application

1 verification period; otherwise, the proposal/application will be reviewed as submitted. If  
2 either the Project Narrative exceeds the page limit or the Budget form contains only zeros, an  
3 updated Grants.gov submission package must be submitted via Grants.gov as a  
4 “Changed/Corrected Application” with the previous Grants.gov Tracking ID.

### 5 **II.H.1.c. Withdrawal**

6 The following may result in administrative withdrawal of the pre-proposal/pre-application or  
7 proposal/application:

- 8 • An [FY18 JPC-1 Medical Simulation and Training Steering Committee member](#) is named as  
9 being involved in the research proposed or is found to have assisted in the pre-proposal/  
10 pre-application or proposal/application processes including, but not limited to, concept  
11 design, proposal/application development, budget preparation, and the development of any  
12 supporting documentation. *A list of the Steering Committee members can be found at:*  
13 <http://cdmrp.army.mil/dmrdp/jpc1msisrp.shtml>.
- 14 • The proposal/application fails to conform to this BAA description to the extent that  
15 appropriate review cannot be conducted.
- 16 • An investigator at an intramural organization is named as a collaborator on a  
17 proposal/application submitted through an extramural organization, but the  
18 proposal/application does not include a letter from the collaborator’s Commander or  
19 Commanding Officer at the intramural organization that authorizes the collaborator’s  
20 involvement.
- 21 • The resultant award is a contract that exceeds \$700,000 and the offeror is other than a small  
22 business, but the contractor did not submit a subcontracting plan for small business and small  
23 disadvantaged business concerns, in accordance with FAR 19.704 and DFARS 219.704.
- 24 • Inclusion of URLs, with the exception of links in References Cited and Publication and/or  
25 Patent Abstract sections.
- 26 • Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- 27 • To preserve the integrity of its peer and programmatic review processes, the CDMRP  
28 discourages inclusion of any employee of its review contractors having any role in the  
29 preparation, research or other duties for submitted proposals/applications. For FY18, the  
30 identity of the peer review contractor may be found at the CDMRP website  
31 (<http://cdmrp.army.mil/about/2tierRevProcess.shtml>). The programmatic review is performed  
32 by the FY18 JPC-1.MSIS Medical Simulation and Training Technologies Steering  
33 Committee. Proposals/Applications that include names of personnel from either of these  
34 companies will be administratively withdrawn unless plans to manage COIs are provided and  
35 deemed appropriate by the Government. Refer to the General Submission Instructions,  
36 Appendix 3, for detailed information.

- 1 • Personnel from applicant or collaborating organizations are found to have contacted persons  
2 involved in the review process to gain protected evaluation information or to influence the  
3 evaluation process.
- 4 • The invited proposal/application does not propose the same research project as described in  
5 the pre-proposal/pre-application.
- 6 • The proposal/application budget differs significantly from the budget included in the pre-  
7 proposal/pre-application.
- 8 • Proposals/Applications proposing research involving a comparison with live tissue training.
- 9 • Applications may be administratively withdrawn from further consideration if the applicant  
10 cannot demonstrate access to the relevant study population and resources.

11 **II.H.1.d. Withhold**

12 Proposals/Applications that appear to involve research misconduct will be administratively  
13 withheld from further consideration pending organizational investigation. The organization will  
14 be required to provide the findings of the investigation to the USAMRAA Contracting or Grants  
15 Officer for a determination of the final disposition of the proposal/application.

### III.I. PROPOSAL/APPLICATION SUBMISSION CHECKLIST

Grants.gov Application Components	Upload Order	Action	Completed
SF424 (R&R) Application for Federal Assistance		Complete form as instructed.	
Attachments Form	1	Project Narrative: Upload as Attachment 1 with file name "ProjectNarrative.pdf."	
	2	Supporting Documentation: Upload as Attachment 2 with file name "Support.pdf."	
	3	Technical Abstract: Upload as Attachment 3 with file name "TechAbs.pdf."	
	4	Lay Abstract: Upload as Attachment 4 with file name "LayAbs.pdf."	
	5	Statement of Work: Upload as Attachment 5 with file name "SOW.pdf."	
	6	Impact/Outcomes Statement: Upload as Attachment 6 with file name "Impact.pdf."	
	7	Innovation Statement: Upload as Attachment 7 with file name "Innovation.pdf."	
	8	Human Subject Recruitment and Safety Procedures: Upload as Attachment 8 with file name "HumSubProc.pdf" (if applicable; required for all studies recruiting human subjects).	
	9	Data Management: Upload as Attachment 9 with file name "DataManage.pdf" (if applicable; required for all studies recruiting human subjects).	
	10	Post-Award Project Transition Plan: Upload as Attachment 10 with file name "Transition.pdf."	
	11	Representations: Upload as Attachment 11 with file name "MandatoryReps.pdf."	
	12	Collaborating DoD Military Facility Budget Form(s): Upload as Attachment 12 with file name "MFBudget.pdf," if applicable.	
Research & Related Senior/Key Person Profile (Expanded)		Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.	
		Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.	
		Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.	
		Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field.	

<b>Grants.gov Application Components</b>	<b>Upload Order</b>	<b>Action</b>	<b>Completed</b>
Research & Related Budget		Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.	
Project/Performance Site Location(s) Form		Complete form as instructed.	
R & R Subaward Budget Attachment(s) Form		Complete form as instructed.	

## **APPENDIX I: ACRONYMS AND ABBREVIATIONS**

ACOS/R&D	Associate Chief of Staff for Research and Development
BAA	Broad Agency Announcement
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CICA	Competition in Contracting Act
COI	Conflict of Interest
DFARS	Defense Federal Acquisition Regulation Supplement
DHA	Defense Health Agency
DHP	Defense Health Program
DoD	Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DUNS	Data Universal Numbering System
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
EO	Executive Order
ET	Eastern Time
EXORD	Execute Order
FAD	Funding Authorization Document
FAPIIS	Federal Awardee Performance and Integrity Information System
FAR	Federal Acquisition Regulation
FDA	U.S. Food and Drug Administration
FFRDC	Federally Funded Research and Development Center
FY	Fiscal Year
HIT	Health Information Technology
HQDA	Headquarters, Department of the Army
HRPO	Human Research Protection Office
IPR	Interim Progress Review
IRB	Institutional Review Board
JPC-1	Joint Program Committee 1
LAR	Legally Authorized Representative
M	Million
Med Sim	Medical Simulation
MHS	Military Health System
MIPR	Military Interdepartmental Purchase Request

MSIS	Medical Simulation and Information Sciences
MSISRP	Medical Simulation and Information Sciences Research Program
NPC	Non-Profit Corporation
OASD(HA)	Office of the Assistant Secretary of Defense for Health Affairs
ORCID	Open Researcher and Contributor ID, Inc.
ORP	Office of Research Protections
PAR	Patient at Risk
PH	Psychological Health
PH/TBIRP	Psychological Health/Traumatic Brain Injury Research Program
PI	Principal Investigator
PTSD	Post-Traumatic Stress Disorder
RDT&E	Research, Development, Test, and Evaluation
SAM	System for Award Management
SET	Stress Exposure Training
SIT	Stress Inoculation Training
SMT	Stress Management Training
SOW	Statement of Work
STEM	Science, Technology, Engineering, and Mathematics
STRIVE	Stress Resilience in Virtual Environments
TBI	Traumatic Brain Injury
TRIAGE	Trauma Resiliency Immersive Adaptive Gaming Environment
TRL	Technology Readiness Level
USAMRAA	U.S. Army Medical Research Acquisition Activity
USAMRMC	U.S. Army Medical Research and Materiel Command
USC	United States Code
VA	Department of Veterans Affairs
VRAS	Virtual Reality Adaptive Simulation
WarPREP	Warfighter Preparation, Resilience, Enhancement and Protection